

39	Table of Contents		
40	Purpose	3	
41	Background	5	
42 43	Figure 1: Splice modulating mechanisms of ASOs for the restoration of a function gene product.		
44	Figure 2: RNA knockdown using ASOs	6	
45	Figure 3: Upregulation of wildtype allele transcript using ASOs.	8	
46	Table 1: List of Key Terms	9	
47	Further Resources	11	
48	Variant Assessment	12	
49	Table 2: Explanation of Variant Classification Terms	12	
50	Figure 4: Overview of consensus guidelines document	14	
51	Step 0 - Variant check	15	
52	Step 1 - Assessment of pattern of inheritance and disease type	17	
53	Step 2 - Assessment of pathomechanism of the genetic variant and haploinsufficiency	18	
54	Step 3 - Evaluation of splicing effects	20	
55	Figure 5: Eligible targets for splice correcting ASOs	22	
56	Table 3: Classification of variants for their eligibility towards splice correction	25	
57	Step 4 - Identification of Relevant Guideline	27	
58	Figure 6: Flowchart for the identification of relevant guidelines.	28	
59	Section A - Considerations for Canonical Exon Skipping	29	
60	Figure 7: Overview exon skipping assessment using a hypothetical transcript	29	
61	Figure 8: Determining exon frames.	31	
62	Figure 9: Formation of a new codon as a result of exon skipping	32	
63	Table 4: Classification of variants for their eligibility towards exon skipping	37	
64	Section B - Considerations for Transcript Knockdown	39	
65	Table 5: Classification of variant for their eligibility towards knockdown	41	
66	Section C - Considerations for upregulation from the wildtype allele	43	
67	Addendum	45	
68	Examples	45	
69	Table 6: Example variants and their assessments	45	
70	Useful Tools	49	
71	Abbreviations	51	
72	References	52	
73			

### 74 Consensus guidelines for eligibility assessment of

75 pathogenic variants to antisense oligonucleotide treatments:

- 76 **The N1C VARIANT guidelines**
- 77 [v1.0 September 2024]

78 (written by David Cheerie and Marlen Lauffer on behalf of the N1C Patient Identification Working

79 Group (PIWG))

### 80 Purpose

The N1C VARIANT (Variant Assessments towards Eligibility for Antisense Oligonucleotide Treatment) guidelines provide clinicians, geneticists, and researchers with a framework for analyzing and classifying <u>disease-causing variants</u> for their amenability towards antisense oligonucleotide (ASO) therapies. <u>Specifically, these guidelines are meant to identify genetic</u> <u>variants most likely to benefit from an ASO-based therapy and distinguish these variants from</u> <u>currently less suitable candidates.</u> With these guidelines, assessors should be able to:

- 87
- Identify variants eligible for analysis by these guidelines and utilize publicly available
   databases and resources to assist in the variant analysis process
- Identify variants causing aberrant splicing and assess what type of splice-altering variants
   can be targeted using ASOs
- 92 3. Assess whether a variant is eligible for treatment by exon skipping ASOs
- 4. Assess whether candidate genes and/or variants are eligible for siRNA or ASO-mediated
   transcript knockdown

95
5. Classify variants as either "eligible", "likely eligible", "unlikely eligible", "not eligible", or
96
96 "unable to assess" towards each of splice correction, exon skipping, or transcript
97 knockdown approaches. The definition of each classified variant is dependent on the type
98 of RNA therapy and is further described in each respective section

99 6. Consider strategies for upregulation of wildtype alleles in cases of haploinsufficiency

To follow these guidelines, readers should have an understanding of foundational genetic concepts including, but not limited to, splicing, introns and exons, coding versus non-coding, and DNA variant types (nonsense/stop gain, missense, indels, frameshifts, etc.). While these guidelines will remind assessors of key definitions (canonical splice site, cryptic splice site, etc.), these concepts will not be explained in detail. Assessors should also be familiar with standard variant annotations and pathogenicity classification approaches, including preferably the ACMG-AMP guidelines (Richards et al., 2015).

These guidelines focus on the evaluation of eligibility of a pathogenic genetic variant for ASO treatment. To assess a person's eligibility for ASO treatment, disease- and individual-specific clinical factors have to also be taken into account, which is beyond the scope of these guidelines (Lauffer, van Roon-Mom, Aartsma-Rus, & N = 1 Collaborative, 2024). In some instances, the guidelines do refer to the gene and disease as a necessity for assessment, and this will be pointed out specifically in the respective sections.

114 The guidelines were prepared to the best of our current knowledge and are subject to change, 115 with new knowledge on the topic being generated continuously. These guidelines reflect a general 116 way of evaluating variants, but there are many exceptions to this. Where necessary, we have 117 mentioned relevant exceptions within the text or as footnotes. This also means a variant's 118 classification can change over time and it might thus be useful to re-assess variants at a later 119 stage. Classifications are made for a variant's eligibility towards a specific ASO strategy. For 120 example, a variant might be classified as "not eligible" for splice correction, while also being 121 classified as "likely eligible" for a transcript knockdown.

122

We recommend only assessing disease-causing variants classified as likely pathogenic and
 pathogenic according to the ACMG-AMP guidelines (Richards et al., 2015).

125

For the assessments, all recommendations on suitable tools, websites, and databases to aid in the process are limited to publicly available resources, but, of course, other licensed resources can also be used at an individual's discretion. Instructions on how to use the recommended tools and websites are beyond the scope of these guidelines. Assessors are encouraged to familiarize themselves with the tools by utilizing the respective tools' "help" pages or corresponding research articles.

132

#### 133 Structure of guidelines

134 These guidelines serve as an aid for assessing a given disease-causing variant and are not meant 135 to be read as a whole. Instead, only specific sections need to be read for each assessment. The 136 guideline will first provide the assessor with a background on ASO/siRNA therapies. The 137 guidelines are then divided into 4 steps. Steps 0-2 are necessary to collect information, such as 138 the inheritance pattern or pathomechanism of disease, relevant to each assessment and to decide 139 on the required therapeutic approach. Step 3 is further relevant for each variant assessment and 140 focuses on splicing evaluation, whereas Step 4 provides an overview (Fig. 6) to guide you to 141 relevant sections of the guideline for specific assessments depending on the information gained 142 in Steps 0-3. A quick overview of the structure can be seen in Fig. 4.

143

144 Sections A-C can then be read independently and the section matching the variant under 145 assessment can be selected. Within the guidelines, assessors will be provided with the possibility 146 to jump between sections via hyperlinks.

147

148 At the end of each section, we have formulated important considerations for each assessment.

149 To support the understanding of the guidelines and their use, we have generated several <u>example</u>

assessments and matching training videos as well as a "<u>Variant Eligibility Calculator</u>" that guides

151 through the different steps and sections. The calculator will also aid in identifying the next possible 152 assessment step if a variant is "not eligible" towards one of the strategies.

153

154

## 156 Background

157 ASOs are short, synthetic, single-stranded oligonucleotides that can bind RNA via Watson-Crick

158 base pairing. ASOs can modify protein expression through various mechanisms (Dhuri et al.,

159 2020, Rinaldi & Wood, 2017).

160


#### 161 Splice Modulation

162 The binding of ASOs to splice sites or splice-regulatory elements on the pre-mRNA transcript 163 allows for manipulation of the splicing process, which can lead to (canonical) exon skipping or the 164 restoration of wildtype splicing.

165

ASOs can be used to restore wildtype splicing in individuals whose mechanism of pathogenicity is caused by the activation or creation of cryptic (non-canonical) splice sites, resulting in aberrant splicing of the transcript (Fig. 1A) and, for example, the inclusion of parts of the intron then termed cryptic or pseudoexon. Additionally, canonical exon skipping ASOs can be used to "skip" exons containing the pathogenic variant, to produce a truncated, yet functional, protein product (Fig. 1B) in the case of loss-of-function (LoF) variants. For gain-of-function (GoF) variants, exon skipping

172 can also be applicable, but there is no requirement to generate a functional protein product.




## Figure 1: Splice modulating mechanisms of ASOs for the restoration of a functional gene product.

- A) ASOs can be used to skip a cryptic exon caused by deep-intronic pathogenic variants to restore
   canonical splicing. B) ASOs can be used to skip an in-frame canonical exon containing a
   truncating variant to produce a truncated yet functional gene product.
- 198

In rare circumstances, certain variants, like single nucleotide polymorphisms (SNPs) or
 pathogenic variants, lead to skipping of an exon and subsequently decreased production of
 protein-coding transcripts. It is possible to develop ASOs that will lead to exon inclusion, however,
 the development of such efforts is challenging (Singh, Lee, DiDonato, & Singh, 2015).

#### 204 Transcript Knockdown

In addition to splice modulation, oligonucleotides can bind to the target transcript and downregulate (pre-)mRNA expression (i.e., knockdown ASOs). Knockdown can be achieved with gapmer ASOs and small interfering RNAs (siRNAs). Gapmer ASOs trigger RNase H-mediated cleavage (Fig. 2), while siRNAs trigger the endogenous RNA interference pathway. Both mechanisms can be utilized in cases where the pathomechanism is a result of overexpression, toxic GoF, or dominant-negative (DN) effects (Lauffer, van Roon-Mom, Aartsma-Rus, & N = 1 Collaborative, 2024).



227

203

212

#### 228 Figure 2: RNA knockdown using ASOs.

ASOs can be used to knockdown RNA transcripts which carry variants leading to a toxic GoF protein (shown here), proteins with a DN effect, or overexpressed proteins.

231

#### 232 Increased protein from wildtype transcript


Furthermore, one can consider upregulation from the WT allele, such as targeted augmentation of nuclear gene output (TANGO), as described in Lim et al., 2020, Mittal et al., 2022, Felker et al., 2023, and Liu et al., 2022 (Fig. 3). For disorders caused by haploinsufficiency, one wildtype allele remains intact and functional. ASOs can be utilized to upregulate the gene product from the wildtype allele with the goal of restoring proper gene and cell function.

- 238
- 239 One such approach includes the targeting of poison exons. Poison exons are naturally occurring, 240 highly conserved alternatively spliced exons that result in premature termination when included
- highly conserved alternatively spliced exons that result in premature termination when included in the transcript. An ASO can be designed to skip poison exons and increase the number of
- 242 productive/protein-coding transcripts, with the goal of increasing protein levels (Fig. 3A).

- Additionally, ASOs can be designed to target naturally occurring antisense transcripts which are non-coding RNAs that can act on one or more corresponding transcripts with diverse roles, including RNA interference and RNA masking (Khorkova et al., 2022). In such cases, targeting antisense transcripts using ASOs can upregulate transcript levels (<u>Fig. 3B</u>).

Lastly, one can target untranslated regions (UTRs) to upregulate or stabilize productive transcripts (Liang et al., 2017; Sasaki et al., 2019). One possible method is the targeting of the upstream open reading frames (uORF). These are alternative reading frames that occur upstream (5') from the canonical reading frame (primary ORF, pORF). These reading frames may code for proteins, but can also downregulate the reading of the canonical reading frame. ASOs targeting the uORF can be used to upregulate transcripts from the canonical reading frame. This can either be done by blocking the uORF or by skipping the exon containing the uORF. A related method is the targeting of the 3' UTR. By using ASOs to interfere with degrading complexes, one can attempt to increase RNA half-life and increase gene product (Fig. 3C).

- 259 Overall, the upregulation of wildtype gene products is a possible approach for disorders caused 260 by haploinsufficiency.



#### **Figure 3: Upregulation of wildtype allele transcript using ASOs.**

A) An ASO can be used to skip a poison exon in a transcript that would usually lead to nonsense mediated decay, increasing wildtype transcript levels and subsequent gene product. B) ASOs can
 target NATs which negatively impact transcription of the sense transcript. By disrupting NAT
 transcription, the wildtype transcript can be increased. C) Targeting uORFs with an ASO can be
 used to promote translation of the pORF (primary open reading frame), increasing wildtype gene
 product.

ASOs offer a potential avenue for the treatment of rare genetic diseases, although this is currently mainly focused on disorders impacting the central nervous system (brain, spinal cord, retina), or liver, due to restricted delivery options. FDA- and EMA-approved ASO therapies include, for example, nusinersen for spinal muscular atrophy (Egli & Manoharan, 2023). The use of ASOs to develop variant-specific therapies has, for example, been demonstrated through milasen, an ASO developed at Boston Children's Hospital, to target a deep intronic *MFSD8* variant resulting in cryptic splicing (Kim et al., 2019).

- 340
- To better understand the concepts and guidelines shared in this document, it is important to familiarize yourself with the key terms outlined in <u>Table 1</u>.
- 343

Term	Definition
Branchpoint	<i>cis</i> -acting intronic motif (specific intronic sequence on the same chromosome) required for pre-mRNA splicing, usually an A (adenosine) located 18-40 nucleotides upstream of the acceptor splice site.
Canonical Acceptor Site	RNA sequence recognized by the spliceosome flanking the 3' end of an intron, usually an AU sequence.
Canonical Donor Site	RNA sequence recognized by the spliceosome flanking the 5' end of an intron, usually a GU sequence.
Canonical Splicing	Splicing involving the use of the canonical acceptor and donor sites (see definitions for canonical acceptor site and canonical donor site).
Cryptic Splicing	Cryptic splice sites are naturally occurring splice sites within the genome that are used infrequently. Splicing involving cryptic splice sites, i.e., cryptic splicing, often leads to the incorporation of parts of an intron into the mRNA transcript (cryptic exon or pseudoexon) or the removal of parts of an exon ultimately leading to an early translation stop. Pathogenic variants causing aberrant splicing can for example activate, strengthen, or create a cryptic splice site and thus cause disease.
DNA Tandem Repeats	Short lengths of DNA repeated multiple times within a gene, e.g. CAG repeats in PolyQ disorders.

#### 344 Table 1: List of Key Terms

Hypomorphic Allele	Alleles that show partial loss of function. Sometimes referred to as "leaky" alleles because there is some retention of protein function.
In-Frame Exon	Exon in which the number of base pairs is divisible by 3. Since each amino acid is encoded in one codon made up of three base pairs, removing an exon that is a multiple of 3 will not disrupt the reading frame. While an exon can be divisible by 3, it does not mean that it starts with the first nucleotide of a codon and ends with the last nucleotide of a codon. The exon boundaries and codon boundaries do not necessarily align. See the "Assessing Exon Position and Frame" section in this document.
MANE Select	Matched Annotation from NCBI and EMBL- EBI (MANE): "The MANE Select set consists of one transcript at each protein-coding locus across the genome that is representative of biology at that locus. This set is useful as a universal standard for clinical reporting, as a default for display on browsers and key genomic resources, and as a starting point for comparative or evolutionary genomics. MANE Select transcripts are identified using computational methods complemented by manual review and discussion." (Morales et al., 2022).
Naturally Occurring Antisense Transcript	Noncoding antisense transcripts that can act on one or more corresponding transcripts with diverse roles, including RNA interference and RNA masking.
Out-of-frame Exon	Exon in which the number of base pairs is not divisible by 3. Please see "in-frame exon" for further explanation on exon frames.
Poison Exon	Naturally occurring, highly conserved alternatively spliced exons which result in premature termination when included in the transcript, either as a result of frameshift or the inclusion of a premature stop codon
Protein Tandem Repeat Domain	Two or more domains from the same family found in tandem, e.g. spectrin-like repeats in the dystrophin protein

Splicing	A step in the processing of mature mRNA in which introns (non-coding sequences) are removed or "spliced out" of the pre-mRNA transcript, and the remaining exons (coding sequences) are connected to one another forming the mRNA.
Splicing Enhancer Site (SE)	RNA sequence motif found in the exon/intron of genes, binds proteins that help recruit splicing machinery to the correct site, directing or enhancing accurate splicing.
Splicing Silencer Site (SS)	RNA sequence motif found in the exon/intron of genes, binds proteins that negatively affect the core splicing machinery, inhibiting or silencing the inclusion of an exon into the mRNA.
Upstream Open Reading Frame	Alternative reading frames that occur upstream (5') from the canonical reading frame.

#### 345 Further Resources

- 346 For further resources on the mechanisms and use of ASOs for genetic disorders, please see the
- below recommendations. Note: these additional resources are not required but are encouragedfor those who are not familiar with ASO technology.
- 350 Educational videos
- 351 Treating Disease at the RNA Level with Oligonucleotides:
- 352 https://www.youtube.com/watch?v=nRHypCupg0A
- 354 Modifying RNA splicing with Morpholino Oligos by Gene Tools:
- 355 <u>https://www.youtube.com/watch?v=qu-Kz0HaLxw&ab\_channel=GeneTools</u>
- 356

353

- 357 Overview articles
- 358
- Lauffer et al., *Possibilities and limitations of antisense oligonucleotide therapies for the treatment* of monogenic disorders (10.1038/s43856-023-00419-1) Communications Medicine
- 361
- Hammond et al., *Delivery of oligonucleotide-based therapeutics: challenges and opportunities* (10.15252/emmm.202013243) EMBO Molecular Medicine
- 364
- 365
- 366

## 367 Variant Assessment

- 368 The variant assessment is divided into different steps (please also see flow diagram Fig. 4).
- 369 Step 0 Variant check
- 370 <u>Step 1</u> Assessment of pattern of inheritance and disease type
- 371 Step 2 Assessment of pathomechanism of genetic variant and haploinsufficiency
- 372 <u>Step 3</u> Evaluation of splicing effects
- 373 <u>Step 4</u> Identification of relevant guideline
- 374 <u>Section A</u> Considerations for Canonical Exon Skipping
- 375 <u>Section B</u> Considerations for Transcript Knockdown
- 376 <u>Section C</u> Considerations for upregulation from the wildtype allele
- 377

378 For the assessment of a variant for ASO eligibility, different types of information need to be 379 gathered to decide on suitable ASO strategies and assess a variant using the specific sections 380 (sub-guidelines). To decide on the most suitable guideline for each variant, it is first necessary to 381 check whether the variant can generally be assessed with these guidelines and whether the 382 variant description is correct (Step 0), what the inheritance pattern of the variant and the disorders 383 the gene is associated with are (Step 1), what the pathomechanism of the variant is (Step 2), and 384 whether a variant is influencing splicing (Step 3). With this information at hand, the assessor can 385 decide on possible ASO strategies and read up on the specific sections of the guidelines (Step 4) 386 that will focus on strategies like exon skipping and knockdown approaches.

387

These guidelines are not meant to be read as a whole, but using the information gathered in Steps 1-3, the flow diagram in Fig. 4, and the detailed diagram in Step 4 (Fig. 6) will guide the assessor to the relevant sections. An exception is Step 3 which not only checks for influence on splicing but in case of effects on splicing already allows the assessor to classify the variant with respect to splice correction ASOs.

393

We further provide some notable exceptions and special cases as footnotes. These are cases that apply rarely but were added for the assessors to gain a comprehensive understanding of the assessment process.

397

Variants will be classified as "eligible", "likely eligible", "unlikely eligible", "not eligible", or "unable to assess" towards a specific approach (<u>Table 2</u>) using these guidelines with the exception of upregulation from the wildtype allele (<u>Section C</u>), where no such classification is possible.

401

#### 402 **Table 2: Explanation of Variant Classification Terms**

Classification	Explanation
Eligible	Variants are considered eligible when functional evidence supports the effectiveness of an ASO approach. What type of functional evidence is deemed sufficient depends on the approach and is defined within the different sections below.

Likely eligible	Variants are considered likely eligible variants when the variant could potentially be targeted by an ASO, although no functional evidence is currently available to confirm this. That means a variant meets all criteria relevant for ASO development on paper.
Unlikely eligible	Variants are considered unlikely eligible variants when the molecular criteria suggest an ASO is, with our current understanding, unlikely to be effective, but no functional evidence directly contradicts the potential use of an ASO.
Not eligible	Variants are considered not eligible when an ASO approach will not work. This can be the case if the genetics do not allow for an ASO correction or an ASO cannot be designed. It could also be that there is evidence that demonstrates an ASO approach will not work. For example, exon skipping leads to a non- functional protein.
Unable to assess	All variants that currently cannot be assessed with these guidelines. This can be due to the variant not being applicable to these guidelines or that not enough information is available on a variant that allows for it to be assessed.

404 <u>Please note that variants can be applicable and assessed for different approaches and while a</u> 405 variant might be "unlikely eligible" for splice correction, it could for example still be "(likely) eligible"

406 for exon skipping.

407


The guidelines are also provided with a set of <u>example</u> variant assessments found at the end of this document. Videos accompanying the example assessments walk the assessors through the assessments to aid with training. Assessors can further use the test variants that were assessed during the consenting process for further practice. All test variants can be found in Suppl. File 2 and answer keys are provided in Suppl. File 3.

413

414 We have developed the N1C Variant Eligibility Calculator 415 (https://eligibilitycalculator.n1collaborative.org/) - a type of interactive decision tree - that guides 416 the assessor through the assessments and helps with identifying the most suitable section and 417 provides the classifications after answering a set of questions. The calculator additionally provides 418 a printout of the assessment process with displaying information collected during the assessment 419 and the overall classification of the variant.

420

421



452

#### 453 **Figure 4: Overview of consensus guidelines document.**

The guidelines begin with Step 0, 1, and 2, which highlight the assessment of the variant description, inheritance pattern, and pathomechanisms of the variant. When applicable, the evaluation of splicing effects is considered in Step 3. Dependent on the information gathered in Steps 0-3, readers are directed to Sections A, B, or C. The document is designed in a way in which assessors are directed to relevant sections, and are not required to read the entire document for assessment of a variant.

- 460
- 461

## 462 Step 0 - Variant check

In this step, the assessor will learn which type of genetic variant can be assessed using these
guidelines, and how to ensure that the variant description provided is correct. Without the correct
variant description, an assessment is not possible.

466

467 Variants applicable to these guidelines are restricted to (likely) pathogenic, disease-causing single 468 nucleotide variants, small indels, one or multi-exon deletions or duplications, and single gene 469 deletions or duplications. Currently excluded are variants in non-coding genes, 470 deletions/duplications spanning multiple genes (i.e., contiguous gene syndromes), imprinting 471 defects/uniparental disomy, structural rearrangements (e.g., translocations), and aneuploidies. 472 Additionally, mitochondrial DNA disorders (i.e., variants in the mitochondrial genome) cannot be 473 evaluated with these guidelines. All variants that cannot be evaluated will be classified as "unable 474 to assess". Insertions within coding regions are mostly not applicable unless confined within an 475 exon that can be skipped; insertions in introns can be applicable, one example being milasen 476 (Kim et al., 2019). Repeat expansion disorders can also be assessed using these guidelines but 477 the pathomechanism should be well understood to evaluate for knockdown approaches or exon 478 skipping approaches.

479

Before starting to assess a variant, it is important to check the accuracy of the variant description. That means, is the gene symbol correct, does the transcript match the variant and is the consequence on protein level denoted accurately? If the variant description is incorrect, the variant should be classified as "unable to assess" and the description be corrected and verified. These guidelines work with the MANE select transcript but apply to any other transcript also. Choosing a different transcript when it has more biological relevance in a given disease context is preferred.<sup>1</sup>

487

To check a variant and its description, please follow the <u>HGVS nomenclature</u>. Correct variant description and matching of gene and transcript can be checked with <u>Mutalyzer</u> and <u>VariantValidator</u>. Note, Mutalyzer cannot normalize intronic variants given for a non-genomic reference sequence, i.e., an NM accession number. <u>Examples</u> of variants and their descriptions are provided at the end of these guidelines.

493

#### 494 Considerations for Single Gene Copy Number Variants (CNVs)

For the gain or loss of whole genes, special considerations apply. For the gain of a whole gene,
knockdown strategies should be considered (see <u>Section B</u>). For the loss of a gene with one
functional wildtype copy left, upregulation from the allele should be considered (see <u>Section C</u>).
ASO strategies cannot be applied when no copies of the gene are present, i.e., loss of both gene
copies or loss of one gene copy for hemizygous genes.

- 501
- 502

<sup>&</sup>lt;sup>1</sup> In some instances, variants that are deep intronic in the MANE select transcript are exonic in another transcript and are disease-causing due to the effect they have in that exon. Please pay attention to this exception when evaluating the functional consequences of a variant.

#### 503 Optional ASO Check After a Variant Check

504 To save time for assessors familiar with these guidelines, we recommend checking whether there 505 has already been an ASO/siRNA developed for the variant in guestion (clinically or pre-clinically) 506 immediately after checking the correct variant description. This can mean that an ASO has been 507 developed for the specific variant, e.g., a splice correction ASO or a gapmer ASO, or an ASO has 508 been developed for an exon skipping approach for an exon this variant is located in. It can also 509 be that a gapmer ASO/siRNA is available for the gene in guestion or allele-specific for a SNP that 510 is in phase with the pathogenic variant. When doing this ASO-availability check, it should be 511 ensured that the ASO strategy identified also applies to the variant under assessment. If in doubt, 512 we strongly suggest following the full guidelines and at the end checking for available ASOs. 513 Generally, if an ASO has been developed, it should be carefully evaluated whether there is 514 enough functional evidence that the ASO development was successful. That means, for example, 515 demonstrating restoration of protein levels or rescue of a cellular phenotype. In cases where there 516 is enough functional evidence, the variant can be classified as "eligible", and no further evaluation 517 is necessary<sup>2,3</sup>. To investigate whether an ASO has already been developed, we recommend a 518 thorough search using ClinVar, Pubmed, Google Scholar, and web search, also paying attention 519 to conference abstracts if available. Further, ASO registries are available (e.g. n-Lorem) that can 520 be accessed to identify available ASOs. We also consider it sufficient if there is an ASO/siRNA 521 already in clinical implementation, even if there is not yet published data available. That means if 522 an ASO is available in the registries and has already been administered to one or more 523 individuals, this is sufficient to classify the variant under assessment as "eligible". 524 525 526

<sup>&</sup>lt;sup>2</sup> Please note that if publications are available that test ASOs for a specific variant/exon/gene, one has to carefully read whether the ASO design and development was indeed successful. It could be that ASOs were designed but the transcript or protein level could not be restored. Now it depends whether it might not be possible at all to, for example, skip a canonical exon, or whether another ASO design approach might still be justifiable. Depending on the assessment, that might lead to a "not" for eligibility or a "likely/unlikely" following the guidelines. We generally recommend that at least two independent groups with sufficient functional evidence should have shown that ASO development is not possible to declare a variant "not eligible".

<sup>&</sup>lt;sup>3</sup> In the case of an allele-specific ASO development, please check whether the ASO was developed for the specific variant or for a SNP. For the latter, only if the patient has that exact SNP in phase with the pathogenic variant would that ASO be applicable for that patient. If this is not the case, proceed with the next steps of the assessment.

## Step 1 - Assessment of pattern of inheritance and disease type

536 In this step, assessors will identify the pattern of inheritance of the variant under assessment and 537 the disorders implicated in the disease gene. Understanding the inheritance pattern of the variant 538 and the diseases associated with a gene is crucial to later decide on the most suitable ASO 539 strategy and thus the section to use for the assessment. Different considerations will apply 540 depending on the inheritance pattern.

541

542 The assessor has to identify if the variant is inherited in an autosomal dominant (AD), autosomal 543 recessive (AR), or X-linked manner. Usually, in the case of an (autosomal) recessive inheritance, 544 the variant is either being reported as homozygous or a second variant in trans has been identified 545 (i.e., compound heterozygous), making this step of the assessment straightforward. In the case 546 of X-linked disorders in XY males, the variant will be hemizygous. For (autosomal) dominant 547 inheritance, one variant should be reported either *de novo* or inherited from one of the parents. 548 Should the respective information not be available (e.g., the phase of two variants in an autosomal

549 recessive disease gene), some other steps can be taken to gather the necessary knowledge.

550 The following websites can be used to identify the inheritance pattern of a disease:

- 551 OMIM https://www.omim.org/
- 552 Orphanet <u>https://www.orpha.net/consor/cgi-bin/index.php</u>
- 553 GeneReviews https://www.ncbi.nlm.nih.gov/books/NBK1116/
- 554 Pubmed <u>https://pubmed.ncbi.nlm.nih.gov/</u>
- 555 ClinGen <u>https://www.clinicalgenome.org/</u>
- 556

557 Some genes are implicated in different diseases which can, for example, have an autosomal 558 dominant and recessive pattern of inheritance respectively. In such instances, it is important to 559 identify which pattern of inheritance applies to the specific case. A web search on the variant can 560 be useful. The variant may have been reported in a publication where a pattern of inheritance is 561 noted. Also, gnomAD can be of help. The population frequency of a variant can indicate if the 562 variant is associated with a dominant or recessive inheritance. For example, if a LoF variant has 563 a high allele frequency for heterozygotes but no homozygotes are reported, the variant is more 564 likely to be associated with an AR pattern of inheritance. Similarly, for X-linked disorders in XY 565 males, a lack of hemizygotes would be the equivalent assessment. Further, checking with the 566 diagnostic laboratory or the treating clinician and reviewing the family history can be useful to 567 gather more information on the inheritance pattern in that specific case.

568

569 Should the gene be implicated in different diseases with distinct inheritance patterns, we 570 recommend noting this down as this can help with later steps of the assessment. For example, a 571 gene associated with an AD disorder caused by heterozygous GoF variants and also associated 572 with an AR disorder caused by LoF variants implies that targeting the GoF variants with a 573 knockdown approach is possible but loss of too much of the gene product will also be detrimental.

## 574 Step 2 - Assessment of pathomechanism of the 575 genetic variant and haploinsufficiency

In this step, assessors will identify the pathomechanism of the variant and assess whether the gene in question is associated with haploinsufficiency. The pathomechanism is relevant to decide on the most applicable ASO strategy and with this, the sub-guidelines to use for the assessment. Identifying whether a gene is associated with haploinsufficiency is crucial to deciding whether ASO approaches need to be allele-specific and whether the assessors should consider the guidelines on upregulation from the wildtype allele (see <u>Section C</u>).

- 582
- 583 A pathogenic variant can lead to different effects. The variant can lead to a loss of function of a 584 protein (LoF), toxic gain of function (GoF), or dominant-negative (DN) effect. For an explanation 585 of the different pathomechanisms, please see, e.g., Backwell & Marsh, 2022.
- 586

587 Assessing the variant effect can mostly be done by conducting a web search and reading up on 588 publications and reports of the variant. Resources that can help in identifying the pathomechanism

- 588 publications and reports of the variant. Re 589 associated with a variant are:
- 590 OMIM https://www.omim.org/
- 591 Orphanet https://www.orpha.net/consor/cgi-bin/index.php
- 592 GeneReviews https://www.ncbi.nlm.nih.gov/books/NBK1116/
- 593 Pubmed <u>https://pubmed.ncbi.nlm.nih.gov/</u>
- 594

595 Note that for many variants, no functional studies have yet been performed, especially if the 596 variants are very rare. Thus, we list here some considerations on how to define the 597 pathomechanism:

- 598 Variants with a predicted LoF effect like nonsense and frameshift variants can be assumed 599 in many clinical contexts to result in a null allele in the absence of functional studies (Abou 600 Tayoun et al., 2018). Note that exceptions apply. For example, nonsense or frameshift 601 variants leading to a premature stop codon in the last exon or within 50 bp of 3' end of the 602 penultimate exons may not necessarily lead to loss-of-function. In this case, assessors 603 should take into consideration protein domains and presence of downstream (likely) 604 pathogenic variants (Abou Tayour et al., 2018). In a disease that has only been associated 605 with LoF variants, a newly reported likely pathogenic or pathogenic missense variant may 606 be LoF, especially if this variant is in trans with a known pathogenic LoF variant (for 607 recessive diseases).<sup>4</sup>
- For genes where both LoF and GoF are a known cause of disease, assessing the pathomechanism of a missense variant is challenging. Here, it will become important to take the phenotype and inheritance pattern of the variant into account to make a decision on the pathomechanism of the variant. It can, for example, be possible to predict a pathomechanism in cases where LoF and GoF variants lead to distinguishable

<sup>&</sup>lt;sup>4</sup> We recommend restricting these assumptions to AR diseases because in some cases nonsense and frameshift variants can cause splice aberrations and ultimately lead to a GoF effect on protein level (Flanagan et al., 2017).

613 phenotypes. There are only rare cases where phenotypes are distinct enough to make 614 such a decision. One such example includes distinctly different phenotypes associated 615 with GoF and LoF variants in *GABRB2* patients (Mohammadi et al., 2024). On the other 616 hand, in cases where LoF and GoF variants lead to similar phenotypes as seen in 617 intellectual disabilities, more evidence is necessary and functional studies are crucial. 618 <u>Generally, when in doubt, functional evidence should be obtained.</u>

- 619 DN variants are, by definition, dominant and can thus only be found in dominant disorders.
   620 However, distinguishing whether a variant is GoF or DN might be difficult. Fortunately, for
   621 GoF and DN variants, the ASO approaches are mostly the same.
- There are rare reports of homozygous GoF (Schwarz et al., 2020) variants, thus carefully
   checking the inheritance pattern and pathomechanism is important.
- A missense variant might cause the loss/disturbance of an inhibitory domain causing a toxic gain of function effect of the protein (Mohassel et al., 2021).

627 If sufficient functional evidence does not exist for a given variant, the next step would be to request 628 more information on the variant or experimentally determine the pathomechanism. In the 629 meantime, classify the variant as "unable to assess".

#### 631 Haploinsufficiency

- 632 Besides the identification of the inheritance pattern and the pathomechanism of a variant, the 633 associated gene also needs to be evaluated for haploinsufficiency. Haploinsufficiency refers to a 634 situation in which one healthy, wildtype allele does not generate sufficient protein product to 635 preserve the physiological state (Deutschbauer et al., 2005). In most cases, haploinsufficiency is 636 connected to AD disorders associated with LoF variants; however, several genes have been 637 identified that are associated with LoF variants causing haploinsufficiency, and also GoF variants. 638 That is the case for example for the genes SCN2A and SCN8A (Li et al., 2021; Wagnon et al., 639 2017). Here, GoF and LoF variants cause different clinical presentations depending on the 640 pathomechanism of the variant.
- 641

626

630

The knowledge of whether a gene is associated with haploinsufficiency is important to decide on the best therapeutic approach to assess a variant (see <u>Fig. 6</u>). In brief, for AD disorders caused by LoF variants, in case of haploinsufficiency, the healthy wildtype allele could be upregulated using an ASO strategy (see <u>Section C</u>). For GoF variants, it will be important to assess whether an allele-selective approach is necessary for transcript knockdown (see <u>Section B</u>).

647

To determine whether a gene is associated with haploinsufficiency, different resources can be used. Often, a web search can help as well as GeneReviews.

- 650 GeneReviews https://www.ncbi.nlm.nih.gov/books/NBK1116/
- 651 Pubmed https://pubmed.ncbi.nlm.nih.gov/
- 652

Further indications of whether a gene is associated with haploinsufficiency can be gained from checking the gene constraint metrics like the pLI and LOEUF scores in <u>gnomAD</u>, or the <u>haploinsufficiency score</u> determined by the ClinGen consortium. Additional information on dosage sensitivity in general and how one can assess dosage sensitivity is provided in <u>Section B</u>. We consider a curation from a reputable independent source, such as the ClinGen consortium, the

highest level of evidence for dosage sensitivity/haploinsufficiency.

## 659 Step 3 - Evaluation of splicing effects

660 In this step, assessors will evaluate the effect on splicing of each variant. As explained in the 661 Background, correction of aberrant splicing is an elegant way to restore the reading frame and 662 the physiological splicing pattern (Fig. 1). Thus, the first aim should be to assess whether a splice-663 switching ASO strategy is applicable. Whenever this is not a possibility, the flowchart in Step 4 664 will aid in choosing the most suitable section for variant assessment. For the splicing evaluation 665 and correction of aberrant splicing, different considerations have to be made given inheritance 666 patterns and pathomechanism of the genetic variant (described separately at the end of Step 3). 667 Table 3 provides an overview of the classification of variants for eligibility to ASO splice correction. 668 669 In this section, the following is covered: 670 1. Determining whether a variant affects splicing and what is considered sufficient evidence 671 for mis-splicing 672 2. Considerations for eligibility of splice correction ASOs for both intronic and exonic variants 673 3. Types of exonic variants which can cause aberrant splicing and alternate ASO strategies 674 to consider in place of splice correction 675 4. Important considerations for pathomechanism and inheritance pattern 676 5. How to search the literature for splice correction ASOs 677 678 Different types of variants can influence the splicing process and thus the decision on which ASO 679 strategy to apply. While all variants should be assessed for their splice-altering potential (Anna & 680 Monika, 2018), some exceptions usually do not have to be evaluated in Step 3:

- For nonsense and frameshift variants that are associated with a LoF mechanism at the protein level, see Section A<sup>5</sup> (or Section C in cases of haploinsufficiency). Rare cases where nonsense and frameshift variants that affect splicing lead to GoF or DN effects can be assessed with the considerations outlined in Step 3.
- For whole exon duplications and deletions, please consider the variant effect and jump to
   <u>Section B</u> (knockdown) or <u>Section C</u> (upregulation from the wildtype), check <u>Fig. 6</u> for
   directions.

688

689 The effects on splicing of each variant need to be confirmed with a functional assay, whereby only 690 RNAseq, gPCR, or cDNA sequencing/analysis obtained from patient-derived cells can be 691 considered sufficiently reliable. Please note that it is considered sufficient if functional data of the 692 above-mentioned kind is available on the same variant from a different patient, i.e., a case report 693 in the literature or information provided in ClinVar. Data gathered through mini- and midi-genes 694 cannot be considered sufficient as these assays do not take the full genetic environmental context 695 into account and results can be misleading (Lin et al., 2021). Explicitly, the prediction of splicing 696 effects using *in silico* tools is not sufficient evidence and cannot be used for these assessments 697 (Oh et al., 2024).

<sup>&</sup>lt;sup>5</sup> One notable exception applies here. Nonsense and frameshift variants have a small theoretical probability of resulting in aberrant splicing (Haque et al., 2024). Depending on the splicing effect, this could be canonical exon skipping, in which case the variant is not eligible for exon skipping treatment. It could also be partial exon skipping/cryptic splicing in which the exon in which the variant is located can still be considered for canonical exon skipping, see <u>Section A</u>.

699 In case there is functional evidence against a splice-altering effect, i.e., confirmation that the 700 variant does not affect splicing, please refer to Fig. 6 to guide you towards the next section 701 applicable to your case. Additionally, if there is no functional evidence of splicing effects, please 702 refer to Fig. 6. In the case where there is no evidence of splicing effects (whether for or against), 703 this does not mean the variant is ineligible for splice correcting ASO. A lack of functional evidence 704 towards splicing means this variant cannot be assessed for slice correction eligibility at this time. 705 Theoretically, all variants are suspicious of splicing until demonstrated otherwise, and if evidence 706 on splicing effects becomes available, the variant should be reassessed for eligibility towards 707 splice correction ASOs.

708

709 If splicing effects are confirmed, the exact effects on splicing need to be evaluated. This can be a 710 gain of an acceptor or donor splice site or the loss/weakening of an acceptor or donor splice site. 711 Especially, if canonical splicing is destroyed - due to canonical splice site variants, branchpoint variants, or variants destroying other splice-regulatory elements<sup>6</sup> - the variant is most likely not 712 713 eligible for a splice correction ASO treatment. Canonical splicing is considered destroyed if no 714 wildtype transcript/splicing at the canonical splice sites can be identified in the functional analysis. 715 If some wildtype transcript is still produced or protein function detected, canonical splice sites are 716 considered as weakened. Variants that fully abolish canonical splicing are not amenable to a 717 splice correction ASO and are classified as "not eligible" for this approach.<sup>7,8</sup>

718

719 We recommend studying available data carefully and to also assess data provided in 720 supplementary material, as one can often find relevant gels and blots in the supplement that may 721 only be hinted at in the main manuscript. Further, look out for evidence illustrated by gels or gPCR 722 results etc. instead of solely relying on how the authors describe or discuss the data. From our 723 experience, some manuscripts claim there is no wildtype splicing left whereas faint wildtype bands 724 can be identified in a gel, which might be sufficient to consider this a suitable case. Please 725 consider that a variant's effect on splicing may not have been assessed. The absence of evidence 726 might indicate that splicing effects were overlooked.

727

We generally distinguish intronic and exonic variants for the splicing assessments. Please also see Fig. 5 for a general overview of classification of variants towards splice correction.

730 Intronic variants

As a rule of thumb, we consider intronic variants that are >-100 bp (upstream of acceptor splice site) or >+50 bp (downstream of donor splice site) away from the nearest canonical splice site as

- 733 likely eligible, i.e., there should be no negative impact on the canonical splice sites and
- branchpoint (Fig. 5). For variants closer to the canonical splice sites, enough functional evidence

<sup>&</sup>lt;sup>6</sup> Under certain circumstances, aberrant splicing caused by a destroyed splice enhancer can be counteracted by the steric blocking of a splice silencer. The regulatory element to be blocked should be strong enough and react in *cis* to the affected splice-regulatory element.


<sup>&</sup>lt;sup>7</sup> Two notable exceptions apply here. If the destruction of canonical splicing leads to exon skipping of an out-of-frame exon, skipping of adjacent exons to restore the reading frame can be considered but criteria outlined in <u>Section A</u> apply. If the destruction of canonical splicing leads to a partial skipping of the exon (a few bases are missing - usage of cryptic splice sites) resulting in a frame-shift, ASO-induced canonical exon skipping can be considered for exons that fulfill criteria outlined in <u>Section A</u>.

<sup>&</sup>lt;sup>8</sup> The assessment of whether the wildtype allele is still left can be difficult. For homozygous and hemizygous variants, this is straightforward, but in the case of heterozygous or compound heterozygous variants, this analysis is more difficult and information on the other allele is necessary to assess the effect of a variant.

- should be available on the effect on canonical splicing. Variants within 5 bp of the exonintron/intron-exon boundary are considered "not eligible" for splice correction.<sup>9</sup> Note that the ASO
  should also not disturb the branchpoint, which can vary and is usually found 18-40 bp upstream
  from the acceptor splice site, but can be in 10-100 bp upstream (i.e., -10 to -100 bp region) (Xie,
  Wang, & Lin, 2023).
- 740
- Intronic variants with functional evidence of causing aberrant splicing can now be analyzed using
   the above-mentioned criteria and classified using Table 3.
- 743

#### 744 Exonic variants

For exonic variants, further considerations apply. As for the intronic variants, the exonic variant should be at least 5 bp outside of the canonical splice sites (upstream and downstream - hard cut-off). We further define a second cut off at 15 bp (region 6 to 15 bp upstream or downstream of the canonical splice sites) as a soft cut off where a splice correction can be considered but is challenging. This cut off is based on the idea that ASOs can bind to this region without destroying the canonical splice set, yet there is still a possibility of weakening canonical splicing.



- N Intronic regions not eligible for targeting with ASOs
- Exonic regions eligible for targeting with splice correction ASOs
- Exonic regions close to splice site where ASOs can be considered (unlikely eligible)
- Exonic regions not eligible for targeting with ASOs

#### 751 Figure 5: Eligible targets for splice correcting ASOs

Design of splice correcting ASOs takes into consideration key splicing motifs. The most amenable variants for splice correction are deep intronic variant, highlighted yellow in this figure. As the canonical splice sites are approached, one must consider the effects of the ASO blocking important splice site motifs (i.e., the branchpoint). These regions are highlighted black (intronic) or gray (exonic) in this figure. Anything within 5 bp is considered not eligible for targeting with an ASO (highlighted red in this figure, both intronic and exonic).

<sup>&</sup>lt;sup>9</sup> Avoiding +/-5 bp around the exon-intron/intron-exon boundaries is recommended because these variants are most likely destroying canonical splicing (or the splice site itself) which cannot be corrected. Additionally, it will be challenging to place an ASO within this region without negatively impacting canonical splicing. However, there are currently ongoing research efforts that aim at identifying ways to counteract aberrant splicing caused by variants within this region. Should this approach become feasible in the future, the guidelines will be adjusted.

- 758759 For exonic variants, the specific type of variant is important for further analysis.
- 760 1. Nonsense and frameshift variants that cause aberrant splicing can be further761 distinguished:
- a) If the splice aberration itself leads to a LoF effect on the protein, the variant cannot
   be analyzed using this part of the guidelines. Correction of splicing would still lead
   to a LoF on protein level. Thus, these variants fall under <u>Section A</u> for exon
   skipping analysis (or <u>Section C</u> in the case of haploinsufficiency).
- b) If the splice aberration leads to a toxic GoF effect on protein level, the variant can
  be considered for splice correction. Correction of the splicing effect will then lead
  to an early truncation and most likely a LoF effect on protein level. For certain
  cases, this is a useful ASO approach. It is also possible to consider these variants
  for downregulation (<u>Section B</u>).
- 771In both situations our considerations for haploinsufficiency should be taken into<br/>account.
- 2. Synonymous variants that cause aberrant splicing do not influence the amino acid sequence and can be assessed using <u>Table 3</u>.
- For missense variants and small in-frame indels (<50 bp) (Mahmoud et al., 2019), the considerations are more complicated as both the effect on splicing and also the effect of altering the protein coding sequence need to be taken into account. It needs to be established that the variant effect at the protein level solely arises from the aberrant splicing and not that a missense variant or small indel itself causes a pathogenic effect. It is possible that a missense variant causing aberrant splicing leading to a LoF at the protein level, could independently cause a GoF or DN effect as a missense variant.</li>

783

784

788

789

790

791

792

- a) If the effect of a missense variant or in-frame indel on the protein sequence is not known (independent of the splice-altering effect), the variant cannot be assessed until further evidence is available<sup>10</sup>
- b) If the change in amino acid sequence is known to be pathogenic, for example, if a
  different pathogenic nucleotide change causes the same amino acid change
  without the splicing effect, different sub-criteria apply:
  - Aberrant splicing and missense variant cause GoF/DN effect → can be considered for downregulation (Section B) or for exon skipping (Section A)
  - Aberrant splicing and missense variant cause LoF effect, with the amino acid change causing a complete loss of function on protein level → can be considered for exon skipping (see <u>Section A</u>)
- 793iii)Aberrant splicing causes GoF effect and missense variant would lead to a794 $LoF \rightarrow can be considered for exon skipping (Section A) or knockdown795(Section B) and also for splice correction if the LoF phenotype is milder or796loss of one allele is tolerated797iv)Aberrant splicing causes LoF effect and missense variant causes GoF/DN$ 
  - iv) Aberrant splicing causes LoF effect and missense variant causes GoF/DN effect  $\rightarrow$  can be considered for exon skipping (<u>Section A</u>) or for splice

<sup>&</sup>lt;sup>10</sup> One can consider exon skipping for the variant independent if the variant is LoF, GoF, or DN based on the amino acid change if it is possible to show that the resulting protein has some remaining typical function. Please see <u>Section A</u>.

- 799 correction in case of a GoF effect that leads to a less severe phenotype 800 compared to the LoF phenotype 801 Aberrant splicing leads to GoF or LoF effect and the variant causes partial V) loss of function/reduced protein function  $\rightarrow$  can be considered for splice 802 803 correction and would be classified as "unlikely eligible" for splice correction. 804 Here, the underlying thought is that having a partially functional protein is 805 better than having no protein function or toxic protein function due to 806 aberrant splicing. Variant can also be considered for exon skipping (Section 807 A) or for downregulation (Section B) in case of GoF effects from aberrant 808 splicing. c) If the amino acid change is known to be benign on protein level, due to population 809
- 810 811

data or functional studies, the variant follows the same considerations as a synonymous variant and can be analyzed using Table 3.

#### 813 Important considerations for different inheritance patterns and pathomechanisms

814 For AR disorders, Step 3 applies without restrictions. If the variants are homozygous or compound 815 heterozygous, the Step 3 evaluation has to be done once or twice for both variants. If the disorder 816 is AD associated with a LoF, the Step 3 guidelines also apply. Since the purpose of these ASOs 817 is to restore wildtype splicing, rather than alter splicing, whether the ASO binds the wildtype or 818 pathogenic allele does not matter (unlike with canonical exon skipping ASOs and gapmer ASOs). 819 Similarly, variants that lead to a GoF or DN effect through altering splicing can be assessed with 820 these guidelines (please consider the effect of variant on protein level once splicing is corrected). 821 For GoF or DN variants, however, one might consider a knockdown approach for a more

- 822 efficacious effect (see <u>Section B</u>).
- 823

#### 824 ASO check

In addition to the recommended assessment strategies, assessors should review the literature for splice correcting ASO strategies. This review can be performed either as the final step to validate the assessment strategy or earlier in the assessment process (see <u>Step 0</u>). Specifically, for splice correcting ASOs, it is crucial to evaluate whether a splice correcting approach has been implemented and validated for the specific variant at the RNA level. Please also consider that the rescue at RNA level needs to be sufficient to produce enough protein to rescue the phenotype. Ideally, a publication should provide this evidence.

832

Splicing mechanisms differ by variant, making it crucial to ensure that any existing ASOs found in the literature are applicable to the specific variant of interest. Additionally, if the literature indicates that an ASO is ineffective in correcting splicing for the variant of interest, this does not necessarily render the variant ineligible for ASO development. We recommend that a variant should only be considered "not eligible" for splice-correcting ASOs if there is evidence from two independent investigations at the protein or functional level, or from one investigation providing a convincing explanation as to why an ASO cannot be developed.

840

841 In cases of conflicting evidence, consider the quality of the research, the types of experiments 842 conducted, the nature of the results shared, and the publication date. The evaluation of literature

- 843 on existing ASOs should be carried out at the assessor's discretion, with a critical and discerning 844 approach.
- 845

To help with identifying available ASOs for splice correction, we recommend a search term in Pubmed like this (searching for an ASO targeting a specific variant), text in bold would need to be adjusted for the gene and variant being examined:

- 849 **ABCA4** AND ((ASO) OR (AON) OR (antisense oligonucleotide)) AND ((**GIn876Ter**) OR
- 850 (c.2626C>T) OR (E876X) OR (Q876X) OR (GIn876\*) OR (E876\*) OR (Q876\*))
- 851
- 852 **Table 3: Classification of variants for their eligibility towards splice correction.**

Classification	Criteria
Eligible	ASO has already been developed and shown to work with available
	functional evidence at the protein level (pre-clinical data is sufficient)
Likely eligible	Functional studies (RNAseq, qPCR) validate alternate splicing
	AND (if intronic)
	{
	Intronic variant -101 bp or +51 bp outside of the canonical splice sites
	OR
	No weakened branch point/canonical splice site as determined by functional studies }
	AND (if exonic)
	Donor/acceptor gained is not within 15 bp of a canonical splice site
	AND (if exonic)
	Functional evidence shows there is no pathogenic effect of the amino acid change(s) on the protein.


Unlikely eligible	Functional studies (RNAseq, qPCR) validate alternate splicing
	BUT
	{ Canonical splice site and branchpoint is weakened (but still functional, i.e., either canonical transcript or protein function still detectable)
	OR/AND (if intronic)
	Intronic variant within -6 and -100 bp or +6 and +50 bp of the canonical splice sites.
	OR/AND (if exonic)
	Donor/acceptor gained within 6-15bp of the canonical splice site.
	OR/AND (if exonic)
	There is evidence of residual protein function (i.e., if splicing is corrected, the protein coding change still produces a partially functional protein).
Not eligible	Canonical splice site and branchpoints are destroyed
	OR
	Different nucleotide change leading to the same predicted amino acid residue change – but no alternate splicing – is pathogenic
	OR
	Variant within 5 bp of the canonical splice site
	OR
	Evidence that ASO cannot be developed, shown by two independent investigations on the protein/functional level <b>or</b> one investigation with a convincing explanation of why ASO cannot be developed.

## 857 Step 4 - Identification of Relevant Guideline

In this step, assessors will be guided towards the sections (sub-guideline) applicable to the variant under assessment. Once the inheritance pattern, pathomechanism, and splicing effects are evaluated, a decision on the most useful guideline(s) can be made. If a variant does not have an effect on splicing, or an effect on splicing that cannot be assessed using <u>Step 3</u>, the assessor can turn to the following flow diagram and chart for assistance.

The table within the flow chart lists all applicable sections and with the knowledge of the inheritance pattern and pathomechanism, the assessor can now identify the applicable section(s) to be read to make the assessment.

Please note again that each section is a stand-alone sub-guideline and thus one can jump to the
 necessary section without having to read the full text.



#### 927 Figure 6: Flowchart for the identification of relevant guidelines.

Steps 0, 1, and 2 require the assessment of the variant description, inheritance pattern, and
 pathomechanisms. The evaluation of splicing effects is considered in Step 3. Depending on the
 information gathered in Steps 0-3, one can consider the guidelines discussed in Sections A, B or
 C.

# 932 Section A - Considerations for Canonical Exon 933 Skipping

934

935 In this section, assessors will be guided on how to assess a variant for eligibility towards canonical 936 exon skipping ASOs. As described in the <u>Background</u>, exon skipping ASOs can be used to skip exons containing the pathogenic variant (Fig. 1). Variants generally to be considered for exon 937 938 skipping are nonsense and frameshift variants causing a LoF in AR, AD, and X-linked disorders 939 (additional considerations apply in dominantly inherited diseases, see "Important considerations 940 for different inheritance patterns and pathomechanisms" at the end of this section). GoF and DN 941 negative variants can also be amenable for an exon skipping approach under certain 942 circumstances as well as whole exon deletions (see "Important considerations for different 943 inheritance patterns and pathomechanisms" in this section). While splicing assessments are 944 based on the variant, evaluating the potential for exon skipping are based on the exon, thus an 945 exon skipping approach is applicable to all variants within that exon. For an exon to be skippable, 946 different criteria need to be met (Fig. 7).

#### 947

949

#### 948 This section covers the following topics:

- 1. Assessing exon position and frame
- 950 2. Assessing exon size
- 951 3. Strategies for searching and considering naturally occurring exon skipping and in-frame952 deletions
- 953 4. Assessing the role of functional domains
- 954 5. Important considerations for different inheritance patterns and pathomechanisms
  - 6. Strategies for searching the literature for exon skipping ASOs
- 955 956
- 957

#### 958 Figure 7: Overview exon skipping assessment using a hypothetical transcript.

The first and last coding exons (exon 2 and 10) cannot be skipped, in addition to out-of-frame exons (exons 3,4,7,9, shown by the shape of the exons). In-frame exons encoding for more than 10% of the coding region (exon 5) and exons coding for functional domains (exon 8) are unlikely eligible for exon skipping. Likely eligible for exon skipping are small, in-frame exons that do not code for a domain (e.g., exon 6). White: exon not considered for canonical exon skipping, e.g., exons in the UTRs, grey: Exons not eligible for skipping, blue: exons unlikely eligible for exon skipping, green: exon likely eligible for exon skipping, orange: functional domain.

966


#### 967 Assessing Exon Position and Frame

The first and last coding exon are usually not eligible for exon skipping as this would lead to the loss of the start or stop codon. Note, due to untranslated regions (UTRs) the first and last exons of a transcript are not necessarily coding exons and, thus, assessors should be aware of which

970 exons contain the canonical start and stop codons (Aspden, Wallace, & Whiffin, 2023) (Fig. 7).

972 Additionally, genes containing exactly one coding exon are not eligible and are disqualified from

973 974 975 976	further analysis. Next, assessors should evaluate the length and position/frame of the exon. Out- of-frame exons (containing a number of base pairs not divisible by 3) should be classified as "not eligible" in the case of LoF variants where a restoration of the reading frame is the aim. Assessors can use tools such as the <u>UCSC Genome Browser</u> , <u>ExonViz</u> (van den Berg, Lauffer, & Laros,
977	2024),
978	or Ensembl to determine whether the exon is in-frame or out-of-frame and whether the exon is
979	coding or non-coding ( <u>Fig. 8</u> ).
980	
981	
982	
983	
984	
985	
986	
987	
988	
989	
990	
991	
992	
993	
994	
995	
996	
997	
998	
999	
1000	
1000	
1001	
1002	
1003	
1004	
1005	
1008	
1007	
1009	
1010	
1011	
1012	
1013	
1014	
1015	
1016	
1017	
1018	




#### 1049 Figure 8: Determining exon frames.


1050 A) Exon frames in ExonViz can be identified by their shape. Rectangular shapes are in-frame with a phase at 0-0 (exon starts and ends with the codon). Exons with an arrow on one end and a 1051 1052 notch on the other end are also considered in-frame, whereby it does not matter if the arrow is 1053 upstream or downstream. If there are two arrows or two notches, the exons are out-of-frame. An 1054 arrow indicates a 1 nucleotide overhang while a notch illustrates a 2 nucleotide overhang. Small, 1055 in-frame exons are circled in red (exon 6, 7, 17 and 25). For example, exon 6 starts with an arrow, 1056 meaning the exon starts with 1 nucleotide from a codon starting in the previous exon (i.e., this is 1057 the third nucleotide in the codon, with the first 2 nucleotides being found in exon 5). Exon 6 ends 1058 with a notch, indicating that these are the first two nucleotides of a codon (2-2 phase). In total, 1059 both ends together cover 3 nucleotides. B) Identification with Ensembl can be done by checking 1060 the phases of an exon. Exons with phases 0-0, 1-1, 2-2 are in-frame. Additionally, dividing the 1061 exon length by 3 can help determine the frame. C) UCSC Genome Browser shows phases to 1062 determine the frames using mouse over. The browser directly indicates the phase for you. Please 1063 ensure you are hovering over the correct transcript.

For in-frame exons, it is possible that the first and last codon is partially encoded by the adjacent exons (exons with phases 1-1 and 2-2). In this case, the formation of a stop codon is possible at the new exon-exon boundary created by splicing the upstream and downstream exon together. Assessors should evaluate whether joining the adjacent exons would form an in-frame stop codon, coded by either a TAA, TAG, or TGA (Fig. 9). If this is the case, the exon is not eligible for exon skipping (exceptions apply, please see below). Assessors can utilize the <u>UCSC Genome</u> Browser or <u>Ensembl</u> to check (instructions on how to perform this check are provided in video 11,

1071 the NM\_000170.3(GLDC):c.538C>T example).



B) Exon skipping resulting in formation of glycine codon



#### 1072 Figure 9: Formation of a new codon as a result of exon skipping.

When an in-frame exon with phase 1-1 or 2-2 is skipped, the adjacent exons will form a new codon on the new exon-exon boundary. Panel A shows the formation of a stop codon when an ASO is used to skip in-frame exon 2. The "T" nucleotide from exon 1, and "AA" nucleotides from exon 3 join together to form a stop codon. This leads to a premature termination resulting in an absent gene product or a truncated, non-functional product. Panel B shows the formation of a new codon with a functional product. The "GG" nucleotides at the end of exon 1 join the "A" nucleotide at the start of exon 3, upon skipping of exon 2. This codes for glycine.

- 1080
- 1081

1082 The skipping of an exon that disrupts the reading frame (skipping out-of-frame exons, forming 1083 premature termination codons, or skipping the first and last coding exon) tends to be not eligible 1084 for analysis. However, there are exceptions to these rules:

- It is theoretically possible to skip out-of-frame exons to generate a premature termination codon within the last or penultimate exon given that there is some left-over function of the protein (please note that this is theoretically possible one would still have to assess the last exon for the importance of domains and whether this shortened transcript is predicted to undergo nonsense mediated decay)
- It is also possible to skip out-of-frame exons for GoF or DN variants to downregulate
   transcript levels, please see "considerations for different inheritance patterns and
   pathomechanisms" in this section, as well as <u>Section B</u>
- It is theoretically possible to skip an in-frame exon which results in the formation of a stop codon if it is the penultimate exon given that there is some left-over function of the protein (unlikely eligible)
- It is possible to skip adjacent out-of-frame exons if there is a whole exon deletion of an out-of-frame exon to restore the reading frame. Yet, the other criteria on the size of the skipped area (now deletion + skipped exon) and functional domains apply (see below)
- It is theoretically possible to skip consecutive out-of-frame exons so as not to disrupt the reading frame, though designing an ASO that skips two consecutive exons or multiple ASOs may prove to be a challenge
  - It is theoretically possible to skip the first coding exon if a nearby in-frame start codon exists, and the first exon meets exon skipping criteria outlined in <u>Table 4</u>

#### 1104 1105 Assessing Exon Size

Assessors should consider the size of the exon. As per ClinGen recommendations, an in-frame deletion in the size of 10% or more of the coding transcript is considered a strong criterion for loss of protein function (Walker et al., 2023). However, this is protein and exon-dependent (i.e., losing up to 30% of the dystrophin transcript can still result in a functional, truncated protein (Duan, 2016; Gao & McNally, 2015)). For this reason, skipping an exon that encodes for more than 10% of the protein is considered "unlikely eligible", and obtaining functional evidence is the expected next step.

1113

1115

1102

1103

- 1114 The percentage of coding region can be calculated as follows:
- 1116 Exon size as coding region in % = (exon length in bp/3) / length of the protein in aa \*100
- 1117
- 1118 OR
- 1119
- 1120 Exon size as coding region in % = (exon length in bp) / cDNA length of the gene \*100
- 1121
- 1122 Please see this example for the NM\_003793.4(CTSF):c.264del (p.Cys89fs) variant in video 10.
- 1123 The protein is 484 aa in length. Exon 2 is in-frame 0-0 and spans 99 nucleotides. This information
- 1124 can be obtained from Ensembl, UCSC genome browser, and/or UniProt (see video).
- 1125

1126 Exon size in coding region % = (99/3) aa / 484 aa \* 100 = 6.8 %

- There are instances where an exon coding for more than 10% of the protein will be classified as "not eligible". If the exon encodes for more than 10% of the protein and codes for more than one non-repeat domain, this exon should be considered non-skippable and therefore not eligible for exon skipping ASOs. For more detail on assessing the role of functional domains, please see the section titled "Assessing the Role of Functional Domains".
- 1133

#### 1134 Searching for Cases of (Natural) Occurrences of Exon Skipping or In-frame Deletions

Assessors should determine whether exon skipping has already been observed naturally. This information is necessary to further determine whether exon skipping is a suitable option for a given case. There are different ways in which exon skipping can occur naturally and resources such as <u>ClinVar</u>, <u>gnomAD</u>, <u>DECIPHER</u>, <u>ExonSkipDB</u>, and <u>PubMed</u> aid with their identification:

1139 1140

#### A) Canonical splice site or splice region variants

- 1141Assessors should search ClinVar, PubMed, gnomAD, or Decipher to collect data on1142variants that cause splice aberration leading to full exon skipping. This information should1143have been validated by sufficient functional data (e.g., RNAseq or qPCR). Note that also1144variants affecting splicing motifs outside of the splice sites can cause exon skipping and1145would also fall under this category.
- 1146If full exon skipping has been observed and validated and is disease-causing (pathogenic1147variant), this exon (and therefore variants within that exon) is not eligible for exon skipping1148therapy. <u>Please note that *in silico* predictions are not to be used as substitutes for RNAseq</u>1149and qPCR data, and assessors must pay careful attention to what tools were used in the1150assessment of splicing outcomes of canonical splice site variants.
- 1151 If full-length exon skipping has been observed in individuals who do not show signs of the 1152 disease in question (individuals can of course have other diseases) the exon is eligible for 1153 exon skipping. If no evidence of pathogenic or benign exon skipping validated by qPCR 1154 or RNAseq exists, assessors should proceed with the analysis.
- 1155 1156

#### B) Full exon deletions or in-frame deletions within the exon

- Assessors should search ClinVar, PubMed, gnomAD, or Decipher to collect data on in-1157 1158 frame deletions of full-exon deletions within the exon of interest. If in-frame deletions have 1159 been observed and validated to be disease-causing (pathogenic), this exon (and therefore 1160 variants within that exon) are not eligible. If this is the case, no further analysis is required. 1161 However, assessors should pay attention to whether the in-frame deletion creates a stop 1162 codon or new amino acid, as these exons are still eligible for exon skipping via ASO (i.e., 1163 the pathogenicity is possibly a result of premature termination or the change of an amino 1164 acid leading to folding changes and not necessarily the deletion of amino acids itself). If 1165 this is the case, assessors should proceed with analysis.
- 1166 If full exon deletions and in some instances larger in-frame deletions are identified in the 1167 general population and classified as benign, this exon can be considered "eligible" for an 1168 exon skipping approach.
- 1169

1170 The assessment for occurrence of natural exon skipping can easily be summarized as follows:

1171 Eligible - Loss of the exon, either due to splice aberration of genomic deletions, have been 1172 classified as benign

1173 Not eligible - Loss of the exon or larger parts of the exon have been classified as pathogenic

#### 1174 Assessing the Role of Functional Domains

1175 Assessors should also consider the functionality for which the exon codes. To begin, assessors 1176 should identify which domains are coded by the exon using tools such as the UCSC Genome 1177 Browser. Assessors can then search for the role of these amino acids or domains in the literature 1178 using PubMed, or utilize databases such as the Protein Database (PDB) or UniProt. Assessors 1179 should pay attention to the role of these specific domains (i.e., DNA binding domain, catalytic 1180 domains) or amino acids (i.e., specific amino acid known to play an important role in enzyme 1181 activity or protein structure). Sometimes, a web-search with "protein name protein structure" will 1182 also yield the desired results.

1183

1184 Though it is difficult to define the importance of the domain or to predict the effects of exon 1185 skipping on protein function, assessors can consider the following exons as "not eligible" for exon 1186 skipping:

- The exon codes for important amino acid(s) with a known key functional role in the protein,
   or a functionally validated domain (i.e., involved in a catalytic domain, dimerization
   domain, inhibitory domain, etc.)
- The exon is a known mutational hotspot for pathogenic LoF missense variants (tools such as <u>MetaDome</u>, <u>Essential3D</u>, and <u>Franklin</u> can be used to help determine this)
- The exon codes for the only functional domain in the protein (i.e., no possibility of residual function remaining)
  - The exon codes for multiple functional domains and covers more than 10% of the coding region
- 1196 An exon that codes for a functional domain that does **not** meet the above criteria means it can be 1197 considered as "unlikely eligible", indicating the need for functional studies.
- 1198

1194

1195

1199 Additionally, tandem repeat domains can also be considered as "unlikely eligible", assuming the 1200 loss of a repeat (or part of a repeat domain) from the protein will still have residual function (Duan, 1201 Goemans, Takeda, Mercuri, & Aartsma-Rus, 2021). Assessors can utilize the aforementioned 1202 strategies to assess tandem repeat domains. However, in cases where in-frame deletion of a 1203 repeat domain have been reported as pathogenic, or have been functionally proven to disrupt 1204 protein function, these exons would be considered "not eligible". Most suitable are in-frame exons 1205 that contain a single, full repeat of the tandem repeats and no additional domains. For exon 1206 skipping of tandem repeat domains, we recommend that the protein consists of at least 5 tandem 1207 repeats.

- Generally, we encourage contacting experts on a given gene and protein to discuss the role of
  the different domains and whether they consider exon skipping a possibility. Further, when looking
  into functional domains please check the exact role of a domain and the effect of losing the
  domain. For example, skipping an inhibitory domain could lead to a gain of function effect on
  protein level.
- 1214

1215 If the exon codes for less than 10% of the protein, and no functional domain or important amino
1216 acids are coded for by the exon and the exon fulfills other criteria listed in <u>Section A</u>, then the
1217 exon can be considered as "likely eligible". Exons are classified using the criteria outlined in <u>Table</u>
1218 4.

#### 1220 Special considerations for missense variants and small in-frame indels

1221 If a missense variant or small, in-frame indel lead to a LoF on protein level, additional caution is 1222 necessary. These types of variants often indicate that the exon has a specific function even 1223 though no domain might be annotated. This could be that the respective amino acids are crucial 1224 for folding or the function of a certain domain has not yet been established. In these cases, we 1225 recommend paying special attention to other reported pathogenic variants within the exon. Should 1226 there be more pathogenic missense variants and in-frame indels than truncating variants, we 1227 consider this exon "unlikely eligible" for exon skipping.

1228

However, for missense variants within tandem repeat domains, we refer to the criteria outlined in the tandem repeat domain section as this is an exception to this recommendation.

1231

#### 1232 Important considerations for different inheritance patterns and pathomechanisms

1233 The recommendations described above apply without restrictions to LoF variants in recessive 1234 disorders. For LoF variants in AD disorders, one might consider the development of allele-specific 1235 ASOs. This will ensure that exon skipping does not occur on the wildtype transcript and may result 1236 in greater amounts of functional gene product compared to non-allele specific ASOs. Though 1237 specific ASO design is beyond the scope of these guidelines, this may prove challenging and limit 1238 the types of ASOs to be designed.

1239

1240 In the specific case of an AD disorder with an out-of-frame exon deletion, allele-specificity is 1241 necessary otherwise exon skipping is not possible. Here, exon skipping of adjacent out-of-frame 1242 exons has the potential to restore the reading frame on the mutant allele, at the same time exon 1243 skipping of that out-of-frame exon would destroy the reading frame of the wildtype allele.

1244

Further, for AD disorders associated with LoF variants, an upregulation of protein production from the wildtype allele should also be considered as an alternative option to exon skipping (see <u>Section C</u>).

1248

1249 For GoF and DN variants, additional considerations are possible. The guidelines for exon skipping 1250 can be applied as they are, with the exception that toxic GoF caused by the disruption of an 1251 inhibitory domain will not be rescued by skipping the exon containing the inhibitory domain 1252 (Mohassel et al., 2021). For GoF and DN variants, an out-of-frame exon can be skipped, either 1253 the one containing the variant or any other one to downregulate transcript levels. In such a case, 1254 haploinsufficiency of the gene should be taken into account which might require allele-selective 1255 approaches. Generally, for downregulation of a transcript in case of GoF and DN variants, Section 1256 B can be consulted.

#### 1257 ASO check

In addition to the recommended assessment strategies, assessors should review the literature or registries for exon skipping ASO strategies. This review can be performed either as the final step to validate your assessment strategy or earlier in the assessment process (see <u>Step 0</u>). Specifically, for exon skipping ASOs, it is crucial to evaluate whether an exon skipping approach has been implemented and validated at both the RNA and protein levels and shown to have the desired effect on the phenotype.

In cases of conflicting evidence of ASO developments and the feasibility of an ASO therapy,
consider the quality of the research, the types of experiments conducted, the nature of the results
shared, and the publication date. The evaluation of literature on existing ASOs should be carried
out at the assessor's discretion, with a critical and discerning approach.

1269 1270 For exon skipping ASOs specifically, the approach will be applicable to all variants within a given 1271 exon. However, please pay attention to whether an existing ASO would bind to the variant site 1272 and could thus not be used in the case under assessment if it is a different variant. Also check if 1273 the existing target site contains a SNP and the same SNP is present on the correct allele in the 1274 case under assessment. The exon (and therefore variant) is still considered "eligible" for canonical 1275 exon skipping according to the criteria outlined in Table 4 even if the ASO binds to a different 1276 variant site. This, however, means that a new ASO needs to be designed and developed for the variant under assessment. 1277

1278

1279 To help with identifying available ASOs for exon skipping, we recommend a search term in 1280 Pubmed like this, text in bold would need to be adjusted for the gene and exon being examined: 1281 **ABCA4** AND ((ASO) OR (AON) OR (antisense oligonucleotide)) AND (**Exon 17**)

- Classification Criteria Eligible Evidence that exon skipping does not impair protein function (benign canonical splice site variant leading to exon skipping, benign single exon deletion, naturally occurring transcript does not contain exon, or previously tested ASO with evidence of functional protein product). Likely eligible Exon is in-frame AND Exon does **NOT** result in ≥10% loss of protein coding sequence if exon is skipped. AND Exon does not create a stop codon when skipped AND Exon does not code for any functional domains AND None of the exclusion criteria outlined in the "Not eligible" section are met.
- 1282 Table 4: Classification of variants for their eligibility towards exon skipping.

Liplikoly	Exon is in-frame
Unlikely	
eligible	AND
	Exon does not create a stop codon when skipped
	AND
	{
	Exon results in a loss of $\geq$ 10% of coding transcript if exon is skipped <b>AND/OR</b> exon codes for a <u>single</u> functional domain
	}
	AND
	None of the exclusion criteria outlined in the "Not eligible" section are met
Not eligible <sup>11</sup>	Variant is in an out-of-frame exon <b>OR</b>
5	Variant is in first or last coding exon <b>OR</b>
	Variant is in the ONLY coding exon <b>OR</b>
	Exon skipping results in a stop codon <b>OR</b>
	Exon skipping results in the loss of the ONLY functional domain in the protein <b>OR</b>
	Exon encodes for more than 10% of the proteins AND multiple non-repeat domains <b>OR</b>
	Exon codes for functionally proven important domains or amino acids (catalytic site, dimerization domain, inhibitory domains, etc.) <b>OR</b>
	Exon is a known mutational hotspot for (missense) loss-of-function variants <b>OR</b>
	Functional evidence of exon skipping shown to be pathogenic <b>OR</b> Functional evidence of in-frame deletions shown to be pathogenic <b>OR</b> Evidence that an ASO cannot be developed, shown by two independent investigations at the protein/functional level. Or one investigation with a
	convincing explanation why an ASO cannot be developed.

<sup>&</sup>lt;sup>11</sup> Exceptions apply here for GoF and DN variants. Please see full text.

## 1284 Section B - Considerations for Transcript Knockdown

1285 In this section, assessors will be guided on how to assess a variant for eligibility towards 1286 knockdown approaches. As described in the <u>Background</u>, knockdown ASOs/siRNAs can bind to 1287 the target transcript and downregulate (pre-)mRNA expression. Knockdown strategies can be 1288 utilized in cases where the pathomechanism is a result of overexpression, toxic GoF, or DN effects 1289 (Lauffer, van Roon-Mom, Aartsma-Rus, & N = 1 Collaborative, 2024). This section covers the 1290 following topics:

- 1291 1. Considerations for pathomechanism
- 1292 2. Considerations for dosage sensitivity
- 1293 3. Important considerations for different inheritance patterns and pathomechanisms
- 1294 4. Strategies for searching the literature for gapmer ASOs and siRNAs
- 1295

#### 1296 Considerations for Pathomechanisms

Variants to be considered for knockdown approaches using gapmer ASOs or siRNA are (toxic)
 GoF and DN variants and copy number gains. Strategies on how to assess a variant mechanism
 are discussed in <u>Step 2</u>. Please ensure you have sufficient evidence of GoF or DN
 pathomechanism before proceeding further.

1301

#### 1302 Considerations for Dosage Sensitivity

Before proceeding with the development of a knockdown ASO, it is crucial to consider dosage sensitivity and/or haploinsufficiency. Ideally, a knockdown strategy would be employed when lossof-function is not expected to cause disease. However, such cases are rare. More commonly, alterations in gene dosage are an underlying cause of disease and must be considered when developing knockdown ASOs. Here it becomes important to be aware of the different inheritance patterns that are implicated in a gene.

1309

1310 If complete loss-of-function is not tolerated, but the loss of one gene copy is, knockdowns can still 1311 be considered. Resources such as <u>PubMed</u>, pLI scores, LOEUF scores (both available via 1312 <u>gnomAD</u>), <u>DECIPHER dosage sensitivity</u> track (Collins et al., 2022), and <u>ClinGen dosage</u> 1313 <u>sensitivity</u> score can be used to determine this. We consider a curation from a reputable, 1314 independent source, such as the ClinGen consortium, the highest level of evidence for dosage 1315 sensitivity.

1316

An indication whether the loss of one allele is tolerated can also be gained from population databases such as <u>gnomAD</u>; if there are carriers of LoF variants in the general population, it can be assumed that the loss of one allele is safe.. The same considerations apply for carriers of homozygous LoF variants within a gene that implies that the complete loss of this gene is tolerated. Typically, if the loss of one gene copy is not a known cause of disease and has been observed in healthy cohorts, knockdown ASOs can be considered.

1323

Another factor to consider is haploinsufficiency. As described in <u>Step 2</u>, haploinsufficiency refers to a situation in which one healthy, wildtype allele does not generate sufficient protein product to preserve the physiological state (Deutschbauer et al., 2005). One can utilize resources such as gnomAD's pLI and LOEUF scores and ClinGen's dosage sensitivity score (preferred) to determine

1328 whether haploinsufficiency is a cause of disease. Typically, a pLI score of equal to or greater than

- 0.9, the top three deciles of LOEUF scores, or a <u>ClinGen haploinsufficiency score</u> of 3 (sufficient evidence) indicates haploinsufficiency being a cause of disease (please note that this should be verified by functional evidence available in the literature). In cases where haploinsufficiency is a known cause of disease, a knockdown approach should only be considered if the disease caused by haploinsufficiency is less severe than the disorder associated with the GoF or DN variants.
  Though phenotype considerations are beyond the scope of this guideline, one can consider using OMIM, PubMed, and GeneReviews to assess the genotype-phenotype relation.
- 1336

1337 One should also consider whether hypomorphic alleles are a cause of disease. Hypomorphic 1338 alleles are alleles which show partial loss-of-function (sometimes referred to as "leaky" alleles 1339 because there is some retention of protein function). In such cases, it is important to consider 1340 ASO dosage and associated phenotypes, especially if partial loss-of-function is disease causing.

1341

#### 1342 Important considerations for different inheritance patterns and pathomechanisms

For diseases that are tolerant to complete loss of function (knockout), targeting both alleles may be tolerated. The use of an allele-specific ASO targeting a SNP or the variant site should be considered if changes in gene dosage are a known cause of disease. Though this would greatly limit the ASO design, allele-specific ASOs in these scenarios would help ensure that at least 50% of the wildtype function remains (by targeting only the mutant allele).

1348

Another scenario in which allele-specific ASOs should be considered is if the mechanism is dominant-negative. DN variants impact the wildtype product and therefore may result in a functional product loss of greater than 50%. Hence, it is critical that an ASO is designed to specifically target the DN allele while keeping the wildtype product intact to recapitulate as much function as possible.

1354

In the case of X-linked and Y-linked disorders, further considerations are necessary. For males,
downregulation of a gene on the X or Y chromosome can lead to a complete loss of the gene
function and before embarking on such an approach it should be known that this complete loss is
tolerated. For X-linked disorders in females, it should be considered how X inactivation will affect
gene dosage and whether a knockdown approach is safe.

1360

#### 1361 ASO Check

1362 In addition to the recommended assessment strategies, assessors should review the literature for 1363 knockdown ASO/siRNA strategies. This review can be performed either as the final step to 1364 validate the assessment strategy or earlier in the assessment process (see Step 0). Specifically, 1365 for knockdown ASOs, it is crucial to evaluate whether a knockdown approach has been developed 1366 for other DN or GoF variants in the same gene, and that this approach has been validated at the 1367 RNA and protein level and shown to rescue the phenotype (pre-clinical work is sufficient). Take 1368 note if an allele-specific approach was used, as this may limit ASO design and affect outcomes. 1369 Further, an ASO might have been developed that is specific for a variant other than the one under 1370 assessment or a SNP and information on phasing of an individual's variant with that SNP will then 1371 have to be obtained. The gene is still "eligible" for knockdown according to the criteria outlined in 1372 Table 5 even if the already available ASO is not suitable for the case under assessment. This 1373 means a new ASO would have to be designed and developed for that case. 1374

- In cases of conflicting evidence regarding ASO developments and the feasibility of an ASO
  therapy, consider the quality of the research, the types of experiments conducted, the nature of
  the results shared, and the publication date. The evaluation of literature on existing ASOs should
  be carried out at the assessor's discretion, with a critical and discerning approach.
- 1380 To help with identifying available ASOs/siRNA for knockdown approaches, we recommend a 1381 search term in Pubmed like this, text in bold would need to be adjusted for the gene and variant 1382 being examined:
- SCN2A AND ((ASO) OR (AON) OR (antisense oligonucleotide) OR (AOs) OR (siRNA) OR (RNAi)
   OR (gapmer) or (knockdown))
- 1385 SCN2A AND ((ASO) OR (AON) OR (antisense oligonucleotide) OR (AOs) OR (siRNA) OR
   1386 (RNAi)) AND ((p.R853Q) OR (p.Arg853GIn) OR (c.2558G>A))
- 1387

- 1388 Once all this information is collected, one can use <u>Table 5</u> to classify the variant's eligibility 1389 towards ASO knockdowns as "eligible", "likely", "unlikely", or "not eligible".
- 1390 Variants, where not enough evidence exists on the pathomechanism or the dosage sensitivity 1391 cannot be assessed until more evidence is collected.

#### 1392 Table 5: Classification of variant for their eligibility towards knockdown

Classification	Criteria
Eligible	ASO/RNAi/siRNA has already been developed and shown to work with available functional evidence (i.e., evidence of knockdown rescuing function, pre-clinical data is sufficient)
Likely eligible	Variant is Gain-of-Function or Dominant-Negative (functionally proven)
	AND
	{ Gene is tolerant to the reduction of gene dosage (i.e., gene is NOT haploinsufficient)
	AND/OR
	Individuals with heterozygous LoF variants are present in population databases/described in medical literature, such that high penetrance for probably severe disease phenotypes are unlikely }
Unlikely eligible	Variant is Gain-of-Function or Dominant-Negative (functionally proven)
	BUT
	Heterozygous LoF/Haploinsufficiency/Hypomorphic variants has/have been associated with a disease

	Not eligible	Intolerant to reduction (i.e., gene dosage is tightly regulated in humans,
		and knockdown is expected to lead to serious phenotypic consequences)
		OR
		Evidence that an ASO cannot be developed, shown by two independent investigations at the protein/functional level. Or one investigation with a convincing explanation why an ASO cannot be developed.
1393		
1394		
1395		
1396		
1397		
1398		
1399		
1400		
1401		
1402		
1403		
1404 1405		
1405 1406		
1400 1407		
1408		
1409		
1410		
1411		
1412		
1413		
1414		
1415		
1416		
1417		

# Section C - Considerations for upregulation from thewildtype allele

For disorders caused by haploinsufficiency, one functional wildtype gene copy remains. In these situations, one can use ASOs to upregulate the wildtype allele. This approach, also known as targeted augmentation of nuclear gene output (TANGO), can include skipping of poison exons, downregulating naturally occurring antisense transcripts, and targeting UTR regulator elements such as upstream open reading frames, all of which can increase the gene product. For a more detailed explanation of these approaches, see the Background and the following publications:

- 1426 1. Lim et al. (2020) https://doi.org/10.1038/s41467-020-17093-9
- 1427 2. Mittal et al. (2022) https://doi.org/10.1016/j.medj.2022.08.006
- 1428 3. Felker et al. (2023) https://doi.org/10.1016/j.gim.2023.100884
- 1429 4. Liu et al. (2022) <u>https://doi.org/10.1093/nar/gkac1094</u>
- 1430

For convenience, the data found in the supplementary tables and databases from the four aforementioned publications have also been compiled into one excel sheet (Suppl File 4). Assessors can use this sheet to look up poison exons, naturally occurring antisense transcripts, and upstream open reading frames found from each of these publications. It is highly encouraged that assessors do not rely on this one resource alone, but also utilize it in conjunction with the other strategies discussed below.

1437

1438 Please note that unlike the other ASO strategies, these guidelines will not provide details on how 1439 to classify variants as "likely", "unlikely", or "not eligible". The upregulation of wildtype transcripts 1440 through the aforementioned strategies heavily depends on the availability of functional evidence 1441 for key regulatory elements. These strategies are not comparable to one another, and different 1442 approaches must be employed depending on the availability of regulatory elements. Instead, 1443 readers can reference this section to learn about the different strategies and resources they can 1444 utilize for their own analyses. However, in case the case of a wildtype upregulation approach has 1445 already been established for a given gene with sufficient functional evidence, we consider a 1446 variant as "eligible" toward wildtype upregulation. This section covers:

- 1447 1. Targeting naturally occurring antisense transcripts
  - 2. Targeting upstream open reading frames
- 1449 3. Targeting poison exons and non-productive alternative splicing events
- 1450

1448

#### 1451 Naturally Occurring Antisense Transcripts

1452 Through downregulating naturally occurring antisense transcripts via gapmer ASOs, it is possible 1453 to upregulate gene expression (Fig. 3). Assessors can utilize resources such as PubMed, UCSC 1454 Genome Browser, HUGO Gene Nomenclature Committee, and Ensembl to search for known 1455 antisense transcripts for a given gene. Additionally, the supplemental table 2 in the paper by Mittal 1456 et al. (2022) has listed all antisense transcripts the authors have identified. Assessors should also 1457 consider the level at which these antisense transcripts are expressed in the tissue of interest. 1458 Databases such as GTEx and the Human Protein Atlas can assist with this. Note that the 1459 existence of an antisense transcripts alone is not enough to consider an ASO development. 1460 Factors such as tissue expression, regulatory function, and orientations of the antisense 1461 transcripts must be well understood before considering this approach.

#### 1462 Upstream Open Reading Frames

An ASO can be designed to targets the regulatory elements in untranslated regions, including uORFs (Fig. 3). Resources such as <u>PubMed</u> and <u>Ribo-uORF</u> can be used to check whether there is a uORF that can be targeted. Additionally, the supplemental table 2 in the paper by Mittal et al. (2022) indicates for which genes uORFs have been identified. Note that not all uORFs act through an inhibitory mechanism, and proper characterization of their mechanism is essential in determining their eligibility as ASO targets. Another possible approach is skipping an exon in the UTR that contains a uORF.

1470

#### 1471 Poison Exons and Non-Productive Alternate Splicing Events

1472 One can design ASOs which target non-productive alternate splicing events including poison 1473 exons (Fig. 3). These ASOs would utilize the splice-switching approaches described in the splice-1474 correction and exon skipping sections to promote canonical splicing of the wildtype transcript. 1475 Resources such as PubMed, Ensembl, VastDB, and the UCSC Genome Browser can aid in 1476 determining alternate splicing events in the transcript of interest. Additionally, supplemental table 1477 2 from Mittal et al. (2022), supplemental data 2 from Lim et al. (2020), and supplemental data 1 1478 from Felker et al. (2023) lists all identified poison exons in these papers. Databases such as GTEx 1479 can further assist by determining the expression level of alternate transcripts in the target tissue. 1480 Note that some alternate splicing events are crucial for the production of important transcripts and 1481 isoforms.

1482

For more resources and strategies on upregulating wildtype gene product, please reference the *Useful Tools* section.

1485

#### 1486 Important considerations for different inheritance patterns and pathomechanisms

1487 The considerations outlined here are mainly applicable to diseases associated with 1488 haploinsufficiency, which is most likely caused by LoF variants in AD disorders. In rare cases, 1489 one could also consider applying upregulation of wildtype allele strategies in X-linked disorders in 1490 females where there is sufficient evidence that upregulation from the second X chromosome is 1491 possible. Please always consider challenges caused due to X inactivation.

1492

#### 1493 ASO Check

1494 Also for the upregulation of wildtype allele approaches, one can search whether specific

1495 strategies already exist, are under development or pursued in clinical trials. Multiple strategies

1496 can be utilized to upregulate gene product from wildtype transcripts, and it is therefore important

to employ a variety of strategies/approaches in the search terms to ensure a comprehensivereview of the field.

1499 While we do not classify the different upregulation approaches, we consider a case/variant as 1500 "eligible" for upregulation if an upregulation strategy has been developed and demonstrated to

- 1500 "eligible" for upregulation if an up1501 work with sufficient evidence.
- 1502
- 1503

## 1504 Addendum

#### 1505 Summary "Unable to assess"

- 1506 A variant is classified "unable to assess" when:
- The variant does not fall into the category of variants for these guidelines, e.g.
   translocations, variants in non-coding genes
- 1509 The variant description is incorrect
- 1510 The inheritance pattern is not known
- 1511 The pathomechanism of the variant is not known
- 1512 Not enough information on dosage sensitivity available (for knockdown)
- 1513 Loss of both copies of a gene due to large/whole gene deletions
- 1514 Intronic variant without sufficient functional information on splicing

## 1515 Examples

1516 The below examples provide variant assessments for different types of variants. Detailed

explanations for all the examples can be found in the accompanying training videos (via <u>YouTube</u>)
or the <u>N1C website</u>).

- 1519 To further practice variant assessments, we encourage new assessors to use the test variants in
- 1520 Suppl File 2 and later check the answer keys in Suppl File 3.

#### 1521 Table 6: Example variants and their assessments

#	Variant and Video Content	Assessment
1	<ul> <li>NM_000350.3(ABCA4):c.2626C&gt;T p.(Gln876Ter)</li> <li>Corresponding video content: <ul> <li>Nomenclature check using Mutalyzer</li> <li>Searching UCSC to determine exon number</li> <li>Searching PubMed for exon skipping ASO</li> <li>Recommendations for continued analysis</li> </ul> </li> </ul>	Eligibility: Eligible for exon skipping ASO Explanation: Correct variant description, variant is loss of function in a recessive disorder. Variant is >15 bp downstream of the nearest splice site and is a nonsense variant considered for exon skipping. Variant is located in exon 17/50 in the <i>ABCA4</i> gene, exon is a small, in-frame exon. Skipping of in-frame exon 17 has been shown in pre- clinical studies (Kaltak et al., 2023).
2	NM_016589.4(TIMMDC1):c.597- 1340A>G Corresponding video content: • Nomenclature check using VariantValidator (and example output of incorrect variant)	Eligibility: Eligible for splice correction ASO Explanation: Correct variant description, variant is loss of function in a recessive gene. Variant is deep intronic and >100 bp from the nearest splice site. Variant has been reported multiple times and the effect on splicing has

	<ul> <li>Searching PubMed for splice- switching ASO</li> </ul>	<ul> <li>been confirmed via RNAseq (Kremer et al., 2017).</li> <li>Variant causes the insertion of a cryptic exon and a premature stop.</li> <li>Pre-clinical data is available that shows evidence of rescue of enzymatic effects upon ASO treatment (Kumar et al., 2022).</li> </ul>
3	<ul> <li>NM_000533.5(PLP1):c.680dup p.(Cys228LeufsTer5)</li> <li>Corresponding video content: <ul> <li>Checking inheritance patterns using OMIM</li> <li>Checking variant mechanism using GeneReviews</li> <li>Using UCSC genome browser to determine exon position</li> <li>Using ExonViz to determine exon frame</li> </ul> </li> </ul>	Eligibility: Not eligible for exon skipping ASO Explanation: Correct variant description, X- linked recessive gene, frameshift variant leading to an early stop can only be considered for exon skipping (Section A). Variant >15 bp upstream of nearest splice site. Exon 5/7 is out-of-frame and thus not eligible.
4	<ul> <li>NM_003793.4(CTSF):c.213+1G&gt;C</li> <li>Corresponding video content: <ul> <li>Checking inheritance patterns using OMIM</li> <li>Checking variant mechanism using ClinVar</li> <li>Assessing splicing effects of variants through a literature search</li> </ul> </li> </ul>	Eligibility: Not eligible for splice correction ASO Explanation: Correct variant description, autosomal recessive gene. Variant is a canonical splice site variant and was shown to lead to skipping of exon 1, leading to disease (Di Fabio et al., 2014). Variant is within 5 bp of canonical splice site.
5	<ul> <li>NM_000277.3(PAH):c.611A&gt;G</li> <li>p.(Tyr204Cys)</li> <li>Corresponding video content: <ul> <li>Checking inheritance patterns using OMIM</li> <li>Checking variant mechanisms using OMIM and a literature search</li> <li>Assessing splicing effects of variants through a literature search</li> <li>Assessing effects of missense variant through a literature search</li> <li>Checking the position of the variant respective to canonical splice sites using UCSC</li> </ul> </li> </ul>	<ul> <li>Eligibility: Unlikely for splice correction ASO</li> <li>Explanation: Correct variant description, variant is in a recessive gene, variant is a missense variant with evidence of effect on splicing.</li> <li>Variant affects mRNA splicing and results in a 32-amino acid deletion of the PAH enzyme (Ellingsen, Knappskog, &amp; Eiken, 1997). Variant is classified as unlikely since Ellingsen et al. could only identify a small change in enzymatic activity when generating the enzyme with the missense variant.</li> </ul>

6	<ul> <li>NM_025152.3(NUBPL):c.815-27T&gt;C</li> <li>Corresponding video content: <ul> <li>Checking inheritance patterns using OMIM</li> <li>Assessing variant mechanisms and splicing effects through a literature search</li> </ul> </li> </ul>	Eligibility: Unlikely eligible for splice correction ASO Explanation: Correct variant description. Variant associated with autosomal recessive disorder. Variant is intronic with evidence of effect on splicing. Variant is not within 5bp of the canonical splice site, but in the 5 to 100 bp region. Variant
		affects a branchpoint. The branchpoint is weakened but not destroyed (30% of wildtype transcript remains) (Maclean, Kimonis, & Balk, 2018). Therefore, this variant is unlikely eligible for splice correction ASO.
7	<ul> <li>NM_024312.5(GNPTAB):c.3503_3504d el p.(Leu1168fs)</li> <li>Corresponding video content: <ul> <li>Searching the literature for an already existing ASO</li> <li>Checking inheritance patterns using OMIM</li> <li>Assessing variant mechanisms and eligibility for exon-skipping using the literature</li> </ul> </li> </ul>	Eligibility: Unlikely eligible for exon skipping ASO Explanation: Correct variant description. ASO exists but has only been validated at the RNA level (not the protein level). Variant is associated with autosomal recessive disorder and is loss-of-function. Variant is in exon 19/21. Exon is in-frame and codes for 4.5% of the coding transcript. A stop codon does not form when exon is skipped. Exon codes for a stealth domain, but does not meet any of the exclusion criteria in Table 3
0		(Matos et al., 2020). Therefore, this variant is unlikely eligible for an exon skipping ASO.
8	<ul> <li>NM_001040142.2(SCN2A):c.5645G&gt;A p.(R1882Q)</li> <li>Corresponding video content: <ul> <li>Nomenclature check using variant validator</li> <li>Inheritance pattern check using OMIM</li> <li>Pathomechanism check using ClinVar and by conducting a literature search</li> <li>Dosage sensitivity assessment using ClinGen, pLI, and the literature</li> <li>Conducting an ASO check</li> </ul> </li> </ul>	Eligibility: Eligible for knockdown Explanation: Correct variant description. ASO exists and has been validated clinically. Variant is associated with an autosomal dominant gain-of-function disorder. Haploinsufficiency and loss-of-function is also a known cause of disease, but is arguably associated with less severe phenotypes. Variant classified as "eligible" because preclinical evidence of knockdown approach exists.

9	NM_001165963.4(SCN1A):c.3733C>T p.(R1245Ter)	Eligibility: Eligible for upregulation of wildtype allele
	<ul> <li>Corresponding video content:</li> <li>Nomenclature check using variant validator</li> <li>Inheritance pattern check using OMIM</li> <li>Pathomechanism check using ClinVar</li> <li>Dosage sensitivity assessment using ClinGen and pLI</li> <li>Checking for upregulation (i.e. TANGO) methods using the literature</li> <li>Conducting an ASO check</li> <li>Brief discussion on other upregulation of wildtype allele approaches using NM_130839.5 (UBE3A):c.67C&gt;T, p.(Arg23*) as an example</li> </ul>	Explanation: Correct variant description. ASO exists and has been clinically validated. Variant is associated with autosomal dominant loss-of-function disorder. Haploinsufficiency and loss-of-function is a known cause of disease. Variant is found in an exon not eligible for canonical exon skipping. Poison exons identified in the literature, and have been clinically validated.
10	<ul> <li>NM_003793.4(CTSF):c.264del</li> <li>p.(Cys89fs)</li> <li>Corresponding video content: <ul> <li>Checking inheritance patterns using OMIM</li> <li>Checking variant mechanism using ClinVar</li> <li>Using UCSC genome browser to determine exon position</li> <li>Using ExonViz and Ensembl to determine exon frame</li> <li>Using RefSeq and UniProt to determine exon size</li> <li>Using UniProt to assess corresponding protein function</li> <li>Recommendations for continued analysis</li> </ul> </li> </ul>	Eligibility: Likely eligible for exon skipping ASO Explanation: Correct variant description, autosomal recessive gene, variant is a frameshift variant, thus can only be assessed for exon skipping (Section A). Exon 2/13 is in- frame, approx. 7% of the protein coding region. Skipping of exon does not create a stop codon. No functional domain is known and no mutational hotspot identified.
11	NM_000170.3(GLDC):c.538C>T p.(Gln285Ter) Corresponding video content: • Inheritance pattern check using OMIM	<b>Eligibility: Not eligible for exon skipping</b> Explanation: Variant description is correct. Variant is associated with autosomal recessive loss-of-function disorder. Variant is not in the first or last codon exon. Variant is not in an out-

	<ul> <li>Pathomechanism check using ClinVar</li> <li>Using UCSC genome browser to determine exon position and frame</li> <li>Using UCSC to check whether exon skipping forms a stop codon</li> </ul>	of-frame exon. However, variant is found in an exon which will form a stop codon if skipped, and the two neighboring exons join together. Therefore, this variant is not eligible towards canonical exon skipping ASOs.
12	<ul> <li>Unable to Assess Examples</li> <li>Corresponding video content: <ul> <li>Example of a mitochondrial variant</li> <li>Example of incorrect variant notation</li> </ul> </li> </ul>	<b>Eligibility: Unable to assess</b> All variants discussed in the video are ineligible for assessment either because they are unable to be assessed by these specific guidelines, or not enough information is available to proceed with assessment.
	<ul> <li>Example of a missense variant with an unknown pathomechanism</li> </ul>	

## 1522 Useful Tools

1523 This is a collection of tools that can be useful during variant assessment. Most of them are already

1524 listed throughout the text. Tools are listed matching the different steps of these guidelines.

#### 1525 Step 0 - Variant check

- 1526 HGVS nomenclature: https://varnomen.hgvs.org/
- 1527 Mutalyzer: <u>https://mutalyzer.nl/</u> (cannot do deep intronic variants in c. notation but works with g.
- 1528 notation)
- 1529 VariantValidator: https://variantvalidator.org/
- 1530

1542

#### 1531 Step 1 - Assessment of pattern of inheritance and disease type

- 1532 Gene Cards: <u>http://www.genecards.org/</u>
- 1533 OMIM: https://omim.org/
- 1534 Gene Reviews: <u>https://www.ncbi.nlm.nih.gov/books/NBK1116/</u>
- 1535 Orphanet: https://www.orpha.net/en/disease
- 1536 Monarch Initiative: <u>https://monarchinitiative.org</u>
- 1537 Gene Curation Coalition: <u>https://thegencc.org/</u>
- 1538 ClinGen: <u>https://www.clinicalgenome.org/</u>
- 1539 gnomAD: <u>https://gnomad.broadinstitute.org/</u> (population frequency of a variant)
- 1540 DisGeNet: https://www.disgenet.org/
- 1541 Gene2Phenotype: <u>https://www.ebi.ac.uk/gene2phenotype</u>
- 1543 Step 2 Assessment of pathomechanism of genetic variant
- 1544 HGMD: https://www.hgmd.cf.ac.uk/
- 1545 DECIPHER: <u>www.deciphergenomics.org/</u>
- 1546 ClinVar: <u>https://www.ncbi.nlm.nih.gov/clinvar/</u>

1547	Mastermind Genomenon: https://mastermind.genomenon.com/
1548	Pubmed: https://pubmed.ncbi.nlm.nih.gov/
1549	Franklin: https://franklin.genoox.com/clinical-db/home
1550	LOVD: https://www.lovd.nl/
1551	Varsome: https://varsome.com/
1552	
1553	Step 3 - Evaluation of splicing effects
1554	HGMD: https://www.hgmd.cf.ac.uk/
1555	DECIPHER: https://www.deciphergenomics.org/
1556	ClinVar: https://www.ncbi.nlm.nih.gov/clinvar/
1557	Mastermind Genomenon: https://mastermind.genomenon.com/
1558	Pubmed: https://pubmed.ncbi.nlm.nih.gov/
1559	Search enginer $\rightarrow$ web-search the variant
1560	
1561	Section A - Considerations for canonical exon skipping
1562	UCSC Genome Browser: <u>https://genome.ucsc.edu/</u>
1563	ExonViz:https://exonviz.rnatherapy.nl/
1564	Ensembl: https://www.ensembl.org/index.html
1565	Metadome: https://stuart.radboudumc.nl/metadome/
1566	UniProt: https://www.uniprot.org/
1567	Protein Database: https://www.rcsb.org/
1568	Alphafold: https://alphafold.ebi.ac.uk/
1569	ES-NDD: https://es-ndd.broadinstitute.org/
1570	Franklin: https://franklin.genoox.com/clinical-db/home
1571	ExonSkip DB: https://ccsm.uth.edu/ExonSkipDB/
1572	
1573	Section B - Considerations for Downregulation
1574	gnomAD for pLI and Loef: https://gnomad.broadinstitute.org/
1575	Dosage sensitivity map: UCSC Genome Browser: News Archives
1576	ClinGen dosage sensitivity curation: <u>https://search.clinicalgenome.org/kb/gene-</u>
1577	dosage?page=1&size=25&search=
1578	DECIPHER dosage sensitivity track:
1579	https://genome.ucsc.edu/goldenPath/newsarch.html#022124
1580	<u>mtps.//genome.desc.edd/golden/ dtt/newsdren.ntm#ozz124</u>
1581	Section C - Considerations for upregulation from the wildtype allele
1582	Antisense transcripts via HUGO: Search results   HUGO Gene Nomenclature Committee
1583	(genenames.org)
1584	Ribo uORF:https://rnainformatics.org.cn/RiboUORF/
1585	GTEx: https://gtexportal.org/home/transcriptPage
1586	VastDB: https://vastdb.crg.eu/wiki/Main_Page
1587	vasibb. <u>milps://vasiab.org.ed/wiki/main_rage</u>
1588	Further tools
1589	Further tools MobiDetails: https://mobidetails.iurc.montp.inserm.fr/MD/
1589	
	ProteinPaint: <u>https://proteinpaint.stjude.org/</u> Proteinatlas: <u>http://www.proteinatlas.org/</u>
1591	Proteinatlas: <u>http://www.proteinatlas.org/</u>
1592	FLIBase - Full length isoforms in cancers and normal tissues: http://flibase.org/#/home

## 1593 Abbreviations

- 1594 AD autosomal dominant
- 1595 AR autosomal recessive
- 1596 ASO Antisense Oligonucleotide
- 1597 CNV company number variant
- 1598 DN dominant negative
- 1599 GoF gain of function
- 1600 HGVS Human Genome Variation Society
- 1601 LoF loss of function
- 1602 NMD nonsense mediated decay
- 1603 ORF open reading frame
- 1604 pORF primary open reading frame
- 1605 SE splice enhancer
- 1606 siRNA small interfering RNA
- 1607 SNP Single nucleotide polymorphism
- 1608 SS splice silencer
- 1609 TANGO targeted augmentation of nuclear gene output
- 1610 uORF upstream open reading frame
- 1611 UTR untranslated region
- 1612 WT wildtype
- 1613
- 1614
- 1615
- 1616

### 1617 References

1618 Aartsma-Rus, A., Garanto, A., van Roon-Mom, W., McConnell, E. M., Suslovitch, V., Yan, W. X.,

1619 .... Yu, T. W. (2023). Consensus guidelines for the design and in vitro preclinical efficacy

1620 testing N-of-1 exon skipping antisense oligonucleotides. *Nucleic Acid Therapeutics*, 33(1),

1621 17-25. doi:10.1089/nat.2022.0060

- Abou Tayoun, A. N., Pesaran, T., DiStefano, M. T., Oza, A., Rehm, H. L., Biesecker, L. G., . . .
  ClinGen Sequence Variant Interpretation Working Group (ClinGen, SVI). (2018).
  Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. *Human Mutation, 39*(11), 1517-1524. doi:10.1002/humu.23626
- Anna, A., & Monika, G. (2018). Splicing mutations in human genetic disorders: Examples,
  detection, and confirmation. Journal of Applied Genetics, 59(3), 253-268.
  doi:10.1007/s13353-018-0444-7
- Aspden, J. L., Wallace, E. W. J., & Whiffin, N. (2023). Not all exons are protein coding: Addressing
  a common misconception. Cell Genomics, 3(4), 100296. doi:10.1016/j.xgen.2023.100296
- Backwell, L., & Marsh, J. A. (2022). Diverse molecular mechanisms underlying pathogenic protein
   mutations: Beyond the loss-of-function paradigm. *Annual Review of Genomics and Human Genetics, 23*(1), 475-498. doi:10.1146/annurev-genom-111221-103208

1634 Cavaco, B. M., Canaff, L., Nolin-Lapalme, A., Vieira, M., Silva, T. N., Saramago, A., . . . Hendy,

1635 G. N. (2018). Homozygous calcium-sensing receptor polymorphism R544Q presents as

- 1636 hypocalcemic hypoparathyroidism. *The Journal of Clinical Endocrinology and Metabolism*,
- 1637 *103*(8), 2879-2888. doi:10.1210/jc.2017-02407

- 1638 Collins, R. L., Glessner, J. T., Porcu, E., Lepamets, M., Brandon, R., Lauricella, C., . . . Talkowski,
- 1639 M. E. (2022). A cross-disorder dosage sensitivity map of the human genome. *Cell*, 185(16),
- 1640 3041-3055.e25. doi:10.1016/j.cell.2022.06.036
- 1641 Deutschbauer, A. M., Jaramillo, D. F., Proctor, M., Kumm, J., Hillenmeyer, M. E., Davis, R. W., .
- 1642 . . Giaever, G. (2005). Mechanisms of haploinsufficiency revealed by genome-wide profiling
- 1643 in yeast. *Genetics, 169*(4), 1915-1925. doi:10.1534/genetics.104.036871
- Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020). *Antisense oligonucleotides: An emerging area in drug discovery and development* MDPI AG.
  doi:10.3390/jcm9062004
- 1647 Di Fabio, R., Moro, F., Pestillo, L., Meschini, M. C., Pezzini, F., Doccini, S., . . . Santorelli, F. M.
- 1648 (2014). Pseudo-dominant inheritance of a novel CTSF mutation associated with type B kufs
  1649 disease. *Neurology*, *83*(19), 1769-1770. doi:10.1212/WNL.000000000000953
- 1650 Drutman, S. B., Haerynck, F., Zhong, F. L., Hum, D., Hernandez, N. J., Belkaya, S., ... Casanova,
- 1651 J. (2019). Homozygous NLRP1 gain-of-function mutation in siblings with a syndromic form
- 1652 of recurrent respiratory papillomatosis. *Proceedings of the National Academy of Sciences of*
- 1653 *the United States of America, 116*(38), 19055-19063. doi:10.1073/pnas.1906184116
- Duan, D. (2016). Dystrophin gene replacement and gene repair therapy for duchenne muscular
  dystrophy in 2016: An interview. *Human Gene Therapy.Clinical Development, 27*(1), 9-18.
  doi:10.1089/humc.2016.001
- Duan, D., Goemans, N., Takeda, S., Mercuri, E., & Aartsma-Rus, A. (2021). Duchenne muscular
  dystrophy. *Nature Reviews Disease Primers*, 7(1), 13. doi:10.1038/s41572-021-00248-3
- 1659 Egli, M., & Manoharan, M. (2023). Chemistry, structure and function of approved oligonucleotide
  1660 therapeutics. *Nucleic Acids Research*, *51*(6), 2529-2573. doi:10.1093/nar/gkad067

- 1661 Ellingsen, S., Knappskog, P. M., & Eiken, H. G. (1997). Phenylketonuria splice mutation
  1662 (EXON6nt-96Ag) masquerading as missense mutation (Y204C). *Human Mutation, 9*(1), 881663 90. doi:10.1002/(SICI)1098-1004(1997)9:1
- Felker, S. A., Lawlor, J. M. J., Hiatt, S. M., Thompson, M. L., Latner, D. R., Finnila, C. R., . . .
  Cooper, G. M. (2023). Poison exon annotations improve the yield of clinically relevant
  variants in genomic diagnostic testing. *Genetics in Medicine, 25*(8), 100884.
  doi:10.1016/j.gim.2023.100884
- 1668 Flanagan, S. E., Düng, V. C., Houghton, J. A. L., De Franco, E., Ngoc, C. T. B., Damhuis, A., ...
- 1669 Ellard, S. (2017). An ABCC8 nonsense mutation causing neonatal diabetes through altered
- 1670 transcript expression. Journal of Clinical Research in Pediatric Endocrinology, 9(3), 260–264.
- 1671 doi:10.4274/jcrpe.4624
- Gao, Q. Q., & McNally, E. M. (2015). The dystrophin complex: Structure, function, and implications
  for therapy. *Comprehensive Physiology*, *5*(3), 1223-1239. doi:10.1002/cphy.c140048
- 1674 Haque, B., Cheerie, D., Birkadze, S., Xu, A. L., Nalpathamkalam, T., Thiruvahindrapuram, B., . .
- 1675 . Costain, G. (2024). Estimating the proportion of nonsense variants undergoing the newly
   1676 described phenomenon of manufactured splice rescue. *European Journal of Human* 1677 *Genetics*, 32(2), 238-242. doi:10.1038/s41431-023-01495-6
- 1678 Kaltak, M., Blanco-Garavito, R., Molday, L. L., Dhaenens, C., Souied, E. E., Platenburg, G., . . .
- 1679 Cremers, F. P. M. (2023). Stargardt disease-associated in-frame ABCA4 exon 17 skipping
- 1680 results in significant ABCA4 function. Journal of Translational Medicine, 21(1), 546.
- 1681 doi:10.1186/s12967-023-04406-x

- 1682 Khorkova, O., Stahl, J., Joji, A., Volmar, C., Zeier, Z., & Wahlestedt, C. (2022). Natural antisense
  1683 transcripts as drug targets. *Frontiers in Molecular Biosciences*, 9, 978375.
  1684 doi:10.3389/fmolb.2022.978375
- 1685 Kim, J., Hu, C., Moufawad El Achkar, C., Black, L. E., Douville, J., Larson, A., . . . Yu, T. W.
- 1686 (2019). Patient-customized oligonucleotide therapy for a rare genetic disease. *The New*
- 1687 England Journal of Medicine, 381(17), 1644-1652. doi:10.1056/NEJMoa1813279
- Kremer, L. S., Bader, D. M., Mertes, C., Kopajtich, R., Pichler, G., Iuso, A., . . . Prokisch, H. (2017).
  Genetic diagnosis of mendelian disorders via RNA sequencing. *Nature Communications, 8*(1), 15824. doi:10.1038/ncomms15824
- 1691 Kumar, R., Corbett, M. A., Smith, N. J. C., Hock, D. H., Kikhtyak, Z., Semcesen, L. N., . . . Gecz,
- J. (2022). Oligonucleotide correction of an intronic TIMMDC1 variant in cells of patients with
  severe neurodegenerative disorder. *Npj Genomic Medicine*, 7(1), 9. doi:10.1038/s41525021-00277-7
- Lauffer, M. C., van Roon-Mom, W., Aartsma-Rus, A., & N = 1 Collaborative. (2024). Possibilities
  and limitations of antisense oligonucleotide therapies for the treatment of monogenic
  disorders. *Communications Medicine*, 4(1), 6-1. doi:10.1038/s43856-023-00419-1
- Li, M., Jancovski, N., Jafar-Nejad, P., Burbano, L. E., Rollo, B., Richards, K., . . . Petrou, S. (2021).
  Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gainof-function epilepsy model. *The Journal of Clinical Investigation, 131*(23), e152079. doi:
  10.1172/JCI152079. doi:10.1172/JCI152079
- Liang, X., Sun, H., Shen, W., Wang, S., Yao, J., Migawa, M. T., . . . Crooke, S. T. (2017). Antisense
  oligonucleotides targeting translation inhibitory elements in 5' UTRs can selectively increase
  protein levels. *Nucleic Acids Research*, *45*(16), 9528–9546. doi:10.1093/nar/gkx632

- Lim, K. H., Han, Z., Jeon, H. Y., Kach, J., Jing, E., Weyn-Vanhentenryck, S., . . . Aznarez, I.
  (2020). Antisense oligonucleotide modulation of non-productive alternative splicing
  upregulates gene expression. *Nature Communications, 11*(1), 3501. doi:10.1038/s41467020-17093-9
- Lin, J., Wu, H., Zou, W., Masson, E., Fichou, Y., Le Gac, G., . . . Chen, J. (2021). Splicing
  outcomes of 5' splice site GT>GC variants that generate wild-type transcripts differ
  significantly between full-length and minigene splicing assays. *Frontiers in Genetics, 12*,
  701652. doi:10.3389/fgene.2021.701652
- 1713 Liu, Q., Peng, X., Shen, M., Qian, Q., Xing, J., Li, C., & Gregory, R. I. (2022). Ribo-uORF: A
- 1714 comprehensive data resource of upstream open reading frames (uORFs) based on ribosome
- 1715 profiling. *Nucleic Acids Research*, *51*(D1), D248-D261. doi:10.1093/nar/gkac1094
- Maclean, A. E., Kimonis, V. E., & Balk, J. (2018). Pathogenic mutations in NUBPL affect complex
  I activity and cold tolerance in the yeast model yarrowia lipolytica. *Human Molecular Genetics, 27*(21), 3697-3709. doi:10.1093/hmg/ddy247
- Mahmoud, M., Gobet, N., Cruz-Dávalos, D. I., Mounier, N., Dessimoz, C., & Sedlazeck, F. J.
  (2019). Structural variant calling: The long and the short of it. *Genome Biology*, *20*(1), 246-
- 1721 7. doi:10.1186/s13059-019-1828-7
- Matos, L., Vilela, R., Rocha, M., Santos, J. I., Coutinho, M. F., Gaspar, P., . . . Alves, S. (2020).
  Development of an antisense oligonucleotide-mediated exon skipping therapeutic strategy
  for mucolipidosis II: Validation at RNA level. *Human Gene Therapy, 31*(13-14), 775-783.
  doi:10.1089/hum.2020.034
- Mittal, S., Tang, I., & Gleeson, J. G. (2022). Evaluating human mutation databases for "treatability"
  using patient-customized therapy. *Med*, *3*(11), 740-759. doi:10.1016/j.medj.2022.08.006

- Mohammadi, N. A., Ahring, P. K., Yu Liao, V. W., Chua, H. C., Ortiz de la Rosa, S., Johannesen,
  K. M., . . . Møller, R. S. (2024). Distinct neurodevelopmental and epileptic phenotypes
  associated with gain- and loss-of-function *GABRB2* variants. *eBioMedicine*, *106*doi:10.1016/j.ebiom.2024.105236
- 1732 Mohassel, P., Donkervoort, S., Lone, M. A., Nalls, M., Gable, K., Gupta, S. D., . . . Bönnemann,
- 1733 C. G. (2021). Childhood amyotrophic lateral sclerosis caused by excess sphingolipid 1734 synthesis. *Nature Medicine*, *27*(7), 1197-1204. doi:10.1038/s41591-021-01346-1
- 1735 Morales, J., Pujar, S., Loveland, J. E., Astashyn, A., Bennett, R., Berry, A., . . . Murphy, T. D.
- 1736 (2022). A joint NCBI and EMBL-EBI transcript set for clinical genomics and research. *Nature,*
- 1737 *604*(7905), 310-315. doi:10.1038/s41586-022-04558-8
- Oh, R. Y., AlMail, A., Cheerie, D., Guirguis, G., Hou, H., Yuki, K. E., . . . Costain, G. (2024). A
  systematic assessment of the impact of rare canonical splice site variants on splicing using
  functional and in silico methods. *Human Genetics and Genomics Advances, 5*(3), 100299.
  doi:10.1016/j.xhgg.2024.100299
- Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., . . . ACMG Laboratory Quality
  Assurance Committee. (2015). Standards and guidelines for the interpretation of sequence
  variants: A joint consensus recommendation of the american college of medical genetics and
  genomics and the association for molecular pathology. Genetics in Medicine : *Official Journal*of the American College of Medical Genetics, 17(5), 405-424. doi:10.1038/gim.2015.30
- 1747 Rinaldi, C., & Wood, M. J. A. (2017). Antisense oligonucleotides: The next frontier for treatment
  1748 of neurological disorders Springer Science and Business Media LLC.
  1749 doi:10.1038/nrneurol.2017.148

- 1750 Sasaki, S., Sun, R., Bui, H., Crosby, J. R., Monia, B. P., & Guo, S. (2019). Steric inhibition of 5'
- 1751 UTR regulatory elements results in upregulation of human CFTR. *Molecular Therapy*, 27(10),
- 1752 1749–1757. doi:10.1016/j.ymthe.2019.06.016
- 1753 Schwarz, J., Pedrazza, L., Stenzel, W., Luis Rosa, J., Schuelke, M., Strasbourg, R. (2020). A new
- 1754 homozygous HERC1 gain-of-function variant in MDFPMR syndrome leads to mTORC1
- hyperactivation and reduced autophagy during cell catabolism. *Molecular Genetics and Metabolism*, 131(1), 126-134. doi: 10.1016/j.ymgme.2020.08.008
- Singh, N. N., Lee, B. M., DiDonato, C. J., & Singh, R. N. (2015). Mechanistic principles of
  antisense targets for the treatment of spinal muscular atrophy. *Future Medicinal Chemistry*,
- 1759 7(13), 1793-1808. doi:10.4155/fmc.15.101
- van den Berg, R. R., Lauffer, M. C., & Laros, J. F. J. (2024). ExonViz: A website and python
  package to visualize transcripts and genetic variants. *medRxiv*, 2024.09.18.24313945.
  doi:10.1101/2024.09.18.24313945
- 1763 Wagnon, J. L., Barker, B. S., Ottolini, M., Park, Y., Volkheimer, A., Valdez, P., . . . Meisler, M. H.
- 1764 (2017). Loss-of-function variants of SCN8A in intellectual disability without seizures.
  1765 Neurology.*Genetics*, *3*(4), e170. doi:10.1212/NXG.0000000000170
- Walker, L. C., Hoya, M. d. I., Wiggins, G. A. R., Lindy, A., Vincent, L. M., Parsons, M. T., ...
  ClinGen Sequence Variant Interpretation Working Group. (2023). Using the ACMG/AMP
  framework to capture evidence related to predicted and observed impact on splicing:
  Recommendations from the ClinGen SVI splicing subgroup. *American Journal of Human Genetics*, *110*(7), 1046-1067. doi:10.1016/j.ajhg.2023.06.002

1771	Wishner, B. C., Ward, K. B., Lattman, E. E., & Love, W. E. (1975). Crystal structure of sickle-cell
1772	deoxyhemoglobin at 5 A resolution. Journal of Molecular Biology, 98(1), 179-194.
1773	doi:10.1016/s0022-2836(75)80108-2

- 1774 Xie, J., Wang, L., & Lin, R. (2023). Variations of intronic branchpoint motif: Identification and 1775 functional implications in splicing and disease. *Communications Biology, 6*(1), 1142.
- 1776 doi:10.1038/s42003-023-05513-7

1778

1779

1780